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The major hurdle for gene therapy is how to develop an efficient gene 
delivery vector with cell-type specificity and minimal toxicity. Non-viral vectors 
are gaining more attention over viral vectors due to the safety consideration in 
clinical use. To achieve efficient plasmid delivery, non-viral vectors are 
modified to mimic the viral vector attributes such as interaction with cell 
surface, membrane fusion and nuclear localization. In our studies, various 
peptide-based vectors were designed rationally for gene delivery. 
Firstly, a peptide-polymer hybrid vector Tat-PEI600 was synthesized in-
house by chemically conjugating a low molecular weight polyethylenimine 
PEI600 to a cell-penetrating peptide Tat. Tat peptide is well known of its ability 
to translocate across the plasma membrane, and PEI600 is able to facilitate 
escape of endocytosed DNA by destabilizing the endosomal membrane within 
the acidic endosomes. Therefore, the Tat-PEI600 conjugate combines the 
unique features of these two materials. The stability of DNA/Tat-PEI600 
conjugate complex is improved as compared to that of the noncovalent ternary 
complex DNA/PEI600/Tat, leading to more effective gene transfer. The Tat-
PEI600 conjugate also provides transgene expression levels similar to that 
afforded by PEI25kDa, a gold standard for non-viral vectors.  
Following the same concept, a series of histidine-rich peptides were 
designed based on the understanding that oligohistidine has endosomal 
buffering capacity, which can result in the rupture of endosomal membrane. 
Different peptides composed of DNA binding domain and oligohistidine were 
evaluated for their biophysical properties and gene transfer efficiency. 
Although the DNA/peptide complexes have similar biophysical properties, the 
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Tat-10H peptide was found to be the most effective vector with 10 histidine 
residues as the optimum oligohistidine sequence. Furthermore, by 
incorporating two cysteine residues into the peptide design, the bis(cysteinyl) 
histidine-rich peptide (C-5H-Tat-5H-C) can mediate more effective gene 
transfer than the Tat-10H peptide and 5H-Tat-5H peptide, as interpeptide 
disulfide bonds can form by air oxidation upon binding to DNA, resulted in 
enhanced stability and transfection efficiency. 
To address the issue of cell-type specificity, a multi-domain recombinant 
polypeptide was constructed for gene transfer to cells expressing brain-
derived neurotrophic factor (BDNF) receptor TrkB. The targeting moiety was 
derived from BDNF loops 1 and 2 while the DNA binding domain was (SPKR)4 
derived from histone H1. Similarly, oligohistidine was included for endosomal 
escape. The recombinant polypeptide was able to facilitate gene delivery to 
TrkB-receptor-positive cells in a dose-dependent manner. However, it could 
also transfect non-specifically the TrkB-receptor-negative cells.    
In summary, a panel of biocompatible peptide-based gene delivery vectors 
were developed to avoid potential problems inherent in viral gene delivery 
vectors. The attractive features of peptide-based vectors include the capability 
of dealing with large genes, ease of preparation in bulk quantities with high 
reproducibility and low cost, stability during storage, and ease of 
administration into patients. Although our attempt of using multi-domain 
polypeptide for targeted gene delivery has failed, it was a step forward to the 
realization of using non-viral vectors in gene therapy.     
 VII 
List of tables 
Table 1.2.1 – Sequences of DNA binding and condensing domains...................16 
Table 1.2.2 – Sequences of cell-penetrating peptides.........................................20 
Table 1.2.3 – Sequences of endosomolytic domains. .........................................23 
Table 1.2.4 – Sequences of nuclear localization signals. ....................................25 
Table 3.1.1 – Biophysical properties of DNA/PEI600 and DNA/PEI600/Tat 
complexes. ..........................................................................................................41 
Table 3.1.2 – Biophysical properties of DNA/Tat-PEI600 conjugate and 
DNA/PEI25 complexes........................................................................................45 
Table 3.2.1 – Biophysical properties of DNA/histidine-rich peptide complexes. ..49 
Table 3.2.2 – Biophysical properties of DNA/C-5H-Tat-5H-C peptide and 
DNA/5H-Tat-5H peptide complexes. ...................................................................56 
Table 3.2.3 – Biophysical properties of DNA/C-5H-Tat-5H-C peptide complexes 
after incubation for different time duration. ..........................................................59 
Table 4.2.1 – Sequences of the histidine-rich peptides used in this study. .........78 
 VIII 
List of figures 
Fig 3.1.1 – Chloroquine and PEI600 improve Tat-mediated gene transfection. ..42 
Fig 3.1.2 – Tat-PEI600 conjugation. ....................................................................44 
Fig 3.1.3 – Covalent attachment of PEI600 improves Tat-mediated gene 
transfection. ........................................................................................................47 
Fig 3.1.4 – Cytotoxicity of Tat-PEI600 conjugate in U251 cells........................48 
Fig 3.2.1 – DNA retardation by histidine-rich peptides. .......................................50 
Fig 3.2.2 – Comparison of transgene expression mediated by histidine-rich 
peptides in U251 and H4 cells.............................................................................52 
Fig 3.2.3 – Covalent linkage between Tat and oligohistidine improves gene 
expression...........................................................................................................53 
Fig 3.2.4 – Endosomolytic property of oligohistidine in Tat-10H peptide. ............55 
Fig 3.2.5 – DNA retardation by bis(cysteinyl) histidine-rich peptide and the 
counterpart without cysteine residues. ................................................................57 
Fig 3.2.6 – Interpeptide disulfide bond formation improves transfection efficiency.
............................................................................................................................60 
Fig 3.2.7 – Comparison of transfection efficiencies between C-5H-Tat-5H-C and 
Tat-10H in different glioma cell lines. ..................................................................61 
Fig 3.2.8 – Estimation of transfection efficiency of different vectors in different 
glioma cell lines as observed by GFP expression. ..............................................62 
Fig 3.2.9 – Cytotoxicity of bis(cysteinyl) histidine-rich peptide in U251 cells. ..64 
Fig 3.3.1 – Induced expression and purification of recombinant polypeptide. .....65 
Fig 3.3.2 – Characterization of DNA/(SPKR)4BL-1,2 complex.............................67 
Fig 3.3.3 – Luciferase reporter gene transfer by (SPKR)4BL-1,2 in TrkB-receptor-
positive cells........................................................................................................69 
Fig 3.3.4 – Luciferase reporter gene transfer by (SPKR)4BL-1,2 in PC-12 cells..71 
Fig 3.3.5 – Comparison of gene transfection efficiencies by PEI25kDa, (SPKR)4 
and (SPKR)4BL-1,2 in NIH-3T3 and HeLa cells. .................................................72 
Fig 4.2.1 – Schematic diagram of interpeptide disulfide bond formation. ............81 
 
 IX 
List of publications 
 
Publications: 
Alexis F., S.-L. Lo and S. Wang, Covalent attachment of low molecular weight 
poly(ethylene imine) improves Tat peptide mediated gene delivery. Adv Mater, 
2006. 18(16): p. 2174-2178 
 
Related publications: 
S.L. Lo and S. Wang, Enhanced Tat peptide mediated gene delivery by 
oligohistidine and disulfide cross-linkage. 2006. (Manuscript prepared) 
 X 
Abbreviations 
AAV adeno-associated virus 
ADA adenosine deaminase 
AFM atomic force microscopy 
BDNF brain-derived neurotrophic factor 
CPP cell-penetrating peptide 
DMEM Dulbecco’s modified Eagle’s medium 
DSC disuccinimidyl carbonate 
EGF epidermal growth factor 
EtBr ethidium bromide 
FBS fetal bovine serum 
FCS fetal calf serum 
Fmoc N-(9-fluorenyl)methoxycarbonyl 
FPLC fast protein liquid chromatography 
GFP green fluorescent protein 
GPC gel permeation chromatography 
HGP Human Genome Project 
HSV herpes simplex virus 
IPTG isopropyl-b-d-thiogalactopyranoside 
N/P amines to phosphates ratio 
NGF nerve growth factor 
NLS nuclear localization signal 
NPC nuclear pore complex 
OTC ornithine transcarbamylase 
PBS phosphate buffer saline 




RLU relative light units 
SCID severe combine immune deficiency 
SCID-X1 X-linked severe combine immunodeficiency 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SV40 simian virus 
TBE Tris-borate-EDTA buffer 
































1.1 Background on Gene Therapy 
The original idea of human gene therapy can be traced back to 1963. In an 
article “Biological Future of Man”,  Joshua Lederberg writes [1] :   
“We might anticipate the in vitro culture of germ cells and such manipulations 
as the interchange of chromosomes and segments. The ultimate application 
of molecular biology would be the direct control of nucleotide sequences in 
human chromosomes, coupled with recognition, selection and integration of 
the desired genes…” 
Considering that the first recombinant DNA experiment in bacteria happened 
only 10 years later [2],  the concept of engineering human cells was quite bold 
and upfront. The  material  support  for  the  gene  therapy concept  came  from  
the  knowledge  of  cell  transformation  by  viruses. Viruses can attack their 
hosts and introduce their genetic material into the host cell as part of their 
replication cycle. Hence, genetic diseases could be treated by introducing the 
desired gene to correct defective genes responsible for disease development. 
Following the first cell-free synthesis of DNA in 1967, Arthur Kornberg said [3]: 
“It may be possible then to attach a gene to harmless viral DNA and use this 
virus as a vehicle for delivering a gene to the cells of a patient suffering from 
a hereditary defect and thereby cure him.” 
Thus, the concept of human genetic engineering was clearly delineated but 
all discussions were just theoretical. Despite concern about the potential misuse 
of human genetic engineering raised among scientists, two unapproved trials 
were carried out in the early 70s and 80s [4]. In 1970, the first trial of in vivo gene 
therapy was carried out with the administration of wild-type Shope papilloma virus 
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to two German girls with arginase deficiency syndrome, in the hope that the viral 
arginase would replace the missing enzyme in the patients. In 1980, another trial 
of ex vivo gene therapy for b-thalassemia was performed in two patients, by 
transplanting bone marrow treated with b-globin-containing plasmid. In light of 
these both unsuccessful and controversial trials,  the  discussions  of  human 
gene therapy  focused  on  the  argument  of  its  place  in  medicine  and  its  
ethical acceptability  rather  than  its  technical  issues  like  efficiency,  targeting  
and disease  models.   
It was not until 1989 that the first approved clinical gene transfer took place. 
In this clinical trial, NeoR gene-marked tumor-infiltrating lymphocytes (TIL) were 
transferred into patients with deadly cancer malignant melanoma [5]. This first 
federally approved human genetic engineering experiment demonstrated that an 
exogenous gene, although only a marker gene, could be safely transferred into a 
patient and the gene could be detected in cells taken back out of the patient. The 
aim was not therapy, but only an investigation of the applicability and acute side-
effects of the method [6]. In late 1990, the first clinical ex vivo trial with a 
therapeutic aim began, concomitant with the beginning of the Human Genome 
Project (HGP) [7, 8]. This trial was performed on a four-year-old girl with a rare 
genetic disease called severe combined immune deficiency (SCID) [9]. The 
genetic defect of this illness lies in the adenosine deaminase (ADA) gene, which 
leaves the patient extremely vulnerable to infection due to the lack of a healthy 
immune system. Dr W. French Anderson and collaborators used retroviruses to 
deliver the correct ADA gene into autologous T lymphocytes and these corrected 
T lymphocytes were then infused intravenously. Although this procedure was 
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not a cure and ADA-corrected T lymphocytes only worked for a few months, 
this was the first proof of therapeutic benefit of gene therapy. 
Following the excitement brought by the first clinical trial in early 90s, the 
next ten years were actually discouraging and disappointing, especially due to 
the death of a patient involved in a clinical gene therapy trial of University of 
Pennsylvania in 1999 [10]. However, the field learned from its mistakes and 
many problems are now better understood with the advance in cellular and 
molecular biology and a better understanding of human genetics. Up until 
year 2005, more than 1000 clinical trials have been carried out worldwide 
[11]. The diseases addressed mainly comprise of cancers (67%), monogenic 
diseases (8.7%), vascular diseases (8.7%), and infectious diseases (6.6%). The 
vectors used in the trials are mainly viruses (65%) such as adenovirus (25%) 
and retrovirus (24%). Th e  gen es t r ans fe r red  include suicide genes (7.4%) 
and genes encoding cytokines (26%), antigens (15%) and tumor suppressors 
(12%). Though no notable clinical successes have been shown so far, gene 
therapy still holds a great promise in treating diseases for which ineffective 
modalities exist or no options are available.  
To date, the clinical trials have been focusing on the genetic modification 
of somatic cells, in an attempt to treat acquired diseases such as cancers. The 
same gene transfer technology may also be used in germline gene therapy 
and enhancement genetic engineering. In contrast to somatic cell therapy, 
germline gene therapy is the manipulation of human germline cells (i.e. the 
egg or sperm). By inserting a gene into the genome of an egg or sperm, the 
children of the patient will have the inserted gene, and hence the hereditary 
genetic diseases could be treated. Although human germline manipulation 
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could be done in principle, this has not been attempted because of various 
ethical considerations associated and the possible long-term negative effects. 
On the other hand, enhancement genetic engineering is not meant to treat 
people with diseases or abnormal. Instead, it involves the attempt to “improve” 
or “enhance” the non-pathological human traits. For instance, the injection of a 
gene that causes muscle to grow can help to recreate damage tissue in 
muscle dystrophy. However, this could be abused by athletes to heighten their 
stamina and hence creating unfair advantage [12]. On top of the ethical 
concerns, the long-term side effects to patients after altering the genetic 
information are unknown and thus unpredictable dangers still exist.  
Beyond all hypes and high expectations, we have to realize that gene 
therapy research will not have a major impact on the practice of medicine 
without the development of effective and sophisticated gene delivery system. 
As basic science continues to progress within the field, the pace will accelerate 
and  gene  therapy  will  almost  certainly  revolutionize  the  practice  of medicine 
in the future and provide an ultimate treatment for a vast range of diseases that 
are plaguing mankind today. 
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1.2 Gene Delivery Vectors 
1.2.1 The importance of gene delivery vectors 
With the completion of Human Genome Project and the advancement of 
functional genomics, the design of therapeutic gene for gene therapy is now 
possible by looking to the most fundamental causes of disease. Therefore, the 
major hurdle to successful gene therapy is not the scarcity of therapeutic 
genes, but the slow development of efficient gene delivery system. The 
simplest delivery technique is the injection of naked DNA into the tissue or 
systemic injection to a blood vessel [13]. Intramuscular injection of naked 
DNA secures a relatively low level of expression, but sufficient for use in DNA 
vaccination [14]. Recent studies in cancer therapy has shown that 
intratumoral injection of naked DNA could result in tumor regression [15]. 
However, low transfection efficiency due to nucleases in the serum and fast 
tissue clearance remains the main disadvantage of using naked DNA [13, 16]. 
Various physical manipulations have been used to improve the gene 
transfer efficiency. One of the methods is electroporation whereby a quick 
voltage shock disrupts the plasma membrane to allow DNA to get into the cell. 
Successful use of electroporation was observed in transfecting muscles, brain, 
skin, liver, and tumors. However, there are no generally accepted optimal 
conditions of electroporation that are suitable for effective transfection due to 
the specificity of every tissue [14]. Another method is “gene-gun” which is 
originally designed for plant transformation. The gun uses low-pressure 
helium to eject cartridges of gold nano-particles into the desired object. 
Vaccination via gene-gun provides an efficient method for immunization. 
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However, the disadvantage of this method is the shallow penetration of DNA 
into the tissue [13].  
Although administration of DNA avoids carrier-related issues like complex 
formation and safety, the specificity is compromised. Hence, non-toxic 
delivery vectors that can deliver foreign genetic materials into specific cell 
types are the ideal means for gene therapy.  
Generally, gene delivery vectors can be categorized into two groups: 
viral and non-viral systems [17]. Viral vectors are viruses derived from 
common human viral pathogens. Non-viral vectors include cationic 
liposomes, cationic polymers and cationic peptides that can 
electrostatically bind to anionic plasmid DNA. Each group has its own 
advantages and limitations which will be discussed below. 
 
1.2.2 Viral vectors 
The propagation of virus depends on the replication cycle which 
involves the infection of host cell, replication of viral genetic materials and 
the release of mature virus particles. So it is possible to take advantage of 
this by introducing a foreign gene into the virus and then use the properties 
of the virus to deliver this gene with high efficiency into the target cells [14]. 
The genomes of these viral vectors are modified to prevent viral replication, 
assembly and infection. The most commonly used viral vectors are derived 
from retroviruses, adenoviruses, adeno-associated viruses (AAV), and 
herpes simplex viruses (HSV). These viral vectors can provide either 
transient (e.g. adenovirus, vaccinia virus) or permanent (e.g. retrovirus, 
adeno-associated virus) transgene expression [18].  
 8 
Viral vectors are currently the most efficient gene delivery systems for 
clinical application. However, there are some inherited limitations that 
prevent viral vectors to become the ultimate solution for gene delivery. 
Although the essential components for viral propagation are removed from 
the viral vector genome, unpredictable side-effects may still exist and thus 
safety issue remains as the major concern. The major challenge facing all 
viral vectors is the immune response of the host. The host defense 
mechanism eliminates the transduced cells by cellular immunity and 
prevents a repeated administration of the vector due to strong secondary 
antibody response boosted by memory cells [19]. To minimize the immune 
response, most of the viral vectors are designed to have their own protein 
synthesis silenced after transduction. However, these “gutless” viral 
vectors still require the full complement of viral structural proteins, which 
might not be able to bypass the host immune response. One instance 
related to this problem is “The Gelsinger tragedy”, in which 18-year old 
Jesse Gelsinger died in a Phase I clinical gene therapy trial in which 
adenoviral vectors were used. Mr. Gelsinger suffered from deficiency of 
ornithine transcarbamylase (OTC), an inherited liver disease that causes 
life-threatening levels of ammonia to build up in the blood. In attempt to 
extend the lifespan of the patient, a crippled form of adenoviral vector 
carrying a normal OTC gene (second generation of adenoviral vector which 
has E1 and E4 genes deleted) was given in escalating doses. Within hour 
of intra-hepatic administration, the adenoviral vector triggered an 
“activation of innate immunity”, followed by a “systemic inflammatory 
response” and he died two days later. However, other patients with same 
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dose and higher antibody titers did not have the same reaction. The 
genetic background that influences the immune response may vary 
between individuals and hence the risks of using viral vectors are 
unpredictable. 
Another safety concern is the insertional mutagenesis of viral vectors 
which can integrate into the chromosomes. In a clinical trial, 10 patients 
with X-linked severe combined immunodeficiency (SCID-X1) were 
transfused with their own bone marrow-derived progenitor and stem cells. 
These cells were transduced ex vivo with a retroviral vector carrying the 
transgene encoding the common g chain of the interleukin-2 receptor (gc), 
the protein that is defective in these patients [20]. Nine out of ten patients 
showed significant long-term improvement but two patients were reported 
to develop T cell leukemia due to insertion of the retroviral vector near the 
promoter of the proto-oncogene LMO2 [21]. The chance of insertional 
oncogenesis (2 out of 10) was surprisingly high and both patients actually 
had the retroviral insertion at the same LMO2 gene locus, which was then 
unlikely to be a random event.  
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1.2.3 Non-viral vectors 
In order to circumvent some of the problems occurring with viral 
vectors such as oncogenic effects and unexpected immune response, 
synthetic non-viral vectors were developed and they appear to be a safer 
alternative for gene delivery. Non-viral vectors are usually cationic in 
nature to complex and condense anionic plasmid DNA into nanoparticles 
through electrostatic interactions. However, the overall surface charge of 
the nanoparticles will remain positive for interaction with negatively 
charged plasma membrane, thereby enhancing their cellular uptake by an 
endocytosis pathway [17, 22]. 
Non-viral vectors have some potential advantages over the viral 
counterparts. They can be non-toxic, non-pathogenic, and with little 
immune response, which will allow large dosage and/or repeated 
administration. They could also provide protection of DNA from 
degradation and resist aggregation under physiological salt conditions [23, 
24]. The therapeutic gene delivered remains episomal and avoids the risk 
of oncogenesis caused by random integration of viral vector. The  transient 
expression  of  the  non-viral  vectors  could  be  easily  overcome  with 
repeated administration. Non-viral vectors may also have large carrying 
capacity for therapeutic gene, which is required for the delivery of either 
antisense oligonucleotides or artificial chromosomes. Also, it is much 
easier to modify a non-viral vector to target a specific cell type than a viral 
one. The manufacturing, formulation, and storage stability have also 
become a real issue for gene delivery vectors. Viruses can only be 
produced in the living cells and quality assurance/quality control (QA/QC) 
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procedures required for good manufacturing practice (GMP) are difficult to 
be implemented. On the other hand, non-viral vectors avoid the use of 
tissues or cells as bioreactors, which in turn simplifies the manufacturing 
and quality control process. In addition, it is possible to prepare non-viral 
gene delivery system for long term storage, by lyophilization (freeze-drying) 
in the presence of lyoprotectants such as sugars [25-27]. All the above 
characteristics suggest that non-viral vectors may be the main vectors for 
routine gene therapy in the future. 
The non-viral vectors can be categorized into several groups: (1) 
liposome-based, (2) cationic polymer-based, and (3) peptide-based. 
Liposome is one of the most studied non-viral vectors after their 
introduction as gene carriers in 1987 [28]. Liposome is a spherical vesicle 
with a membrane composed of a phospholipid bilayer, which can be 
naturally-derived phospholipids with mixed lipid chains or pure components 
such as cationic lipids. Cationic lipids are amphiphilic molecules composed 
of one or two hydrophobic fatty acid side chains (acyl or alkyl), a linker and 
a hydrophilic amino group. The complex of DNA and liposome is usually 
termed “lipoplex”. Anionic DNA will neutralize cationic liposomes, resulting 
in aggregation and hence the lipoplexes are usually administered directly 
after their formation [17]. The formation of lipoplexes depends largely on 
the interaction among lipid molecules in addition to lipid-DNA interaction. 
The hydrophobic segments of lipid molecules are the major determinant for 
the characteristics of the resulting lipoplexes, which results in limited 
control over the parameters like particle size, shape, stability or 
interactions with cell surface, other lipids and DNA [29-31]. 
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Cationic polymers include synthetic polymers that are highly positively 
charged and can complex with DNA to form a nanoparticle, a “polyplex”, at 
physiological pH. In contrast to lipoplexes, the major driving force of 
polyplexes formation is the polymer-DNA interaction. This property leaves 
greater control over the particle characteristics. In addition, the cationic 
polymer have more flexibility in terms of modification such as molecular 
weight, polymer structure and ligand attachment. The most widely studied 
polymers include poly(L-lysine) (PLL) and polyethylenimine (PEI). PLL is 
linear polypeptide with the amino acid lysine repeats [32]. The molecular 
heterogeneity and toxicity at millimolar concentration usually limit their 
general applicability [33, 34]. In addition, PLL polyplexes usually have poor 
transfection ability because they will tend to aggregate and are not able to 
escape from the endosomes. For such cases, co-treatment with 
endosomolytic agents such as chloroquine is needed [35]. While effective 
in vitro, this approach is not feasible for in vivo gene delivery application. 
Recent research shows that it is possible to modify PLL with poly(ethylene 
glycol) (PEG) and fusogenic peptides, which can suppress the aggregation 
of polyplexes and undergo pH-related conformational changes perturbing 
endosomal membranes [36]. In contrast, PEI, a polymer with a basic 
chemical unit of two carbons followed by one nitrogen atom, does not have 
this aggregation problem. The protonable amines in PEI have a buffer 
capacity virtually at any pH value (proton sponge) and hence PEIs are able 
to destabilize the endosomal membrane within the acidic endosomes [37]. 
PEIs with molecular weight of 25,000 Da or greater have high transfection 
efficiency both in vitro and in vivo,  but they also induce rapid necrotic-like 
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changes resulting from perturbation of the plasma membrane and 
activation of a mitochondrially mediated apoptosis [38-40].  
The third group of non-viral vectors is cationic peptide, which contains 
positively charged amino acids (i.e. histidine, lysine and/or arginine) which 
bind to and condense DNA. Peptide-based gene delivery vectors seem to 
be the least developed among the non-viral vectors but they have great 
potentials to be explored [41]. The idea of using peptides for gene delivery 
evolved from the biochemical knowledge that the active sites of enzymes, 
receptor ligands, and antibodies usually involve about 5 to 20 amino acids 
[34]. Thus, the principal advantage of using a peptide-based vector is the 
flexibility to design a peptide which can include specific sequences from 
active sites of native proteins to overcome extra- and intracellular barriers 
to gene delivery. Other advantages of peptide-based vectors are: (1) 
peptide synthesis does not involve complicated instrumental operation or 
chemistry; (2) quality control is relatively easy since the molecular structure 
and purity can be accurately determined and (3) synthetic peptides are 
poorly antigenic due to their low molecular weight [42].  
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1.2.4 Design elements of peptide-based gene delivery vectors 
Having so many advantages over the other vectors, the major 
challenge for peptide-based vectors will be to improve the efficiency of 
gene delivery to a level that surpasses that of viral systems. However, to 
reach such a goal, peptide-based vectors need to overcome a series of 
barriers before becoming transcriptionally active in the nucleus. These 
barriers include extracellular barriers such as the stability of DNA/peptide 
complexes in extracellular environment and cellular uptake by specific cell 
type, as well as intracellular barriers such as the processes of endosomal 
escape, trafficking to the nucleus, nuclear entry and vector unpacking. In 
virtue of the modular, “Lego-like” design offered by peptide, it is possible to 
include various functional domains to overcome all these barriers. 
Therefore, the major components of peptide-based vectors will be: (1) DNA 
binding and condensing sequence; (2) cell-targeting sequence; (3) cell 
penetration sequence; (4) endosomolysis sequence and (5) nuclear 
localization sequence.  
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1.2.4.1 DNA binding and condensing domain 
Under “physiological” conditions (a 0.1 molar solution of NaCl), a DNA 
molecule takes on the form of a disordered coil with a radius of gyration of 
several micrometers [43]. The condensation of DNA into a particle with 
finite size and morphology can resist the nuclease-related degradation for 
extended blood circulation time, which is a pre-requisite for efficient DNA 
delivery [44-46]. DNA condensation is a result of complex interplay of 
different interactions. The minimal functional element needed for DNA 
condensation appears to be a cationic reagent. Polycations can condense 
DNA by neutralizing the negative charges of DNA phosphate groups and 
thus promote hydrophobic interactions of the complexed sites [47-50]. DNA 
condensation requires clusters of three or more cationic charges because 
most monovalent and divalent cations do not condense DNA [51].  
A variety of DNA binding and condensing sequences can be designed 
based on native proteins. DNA binding domains derived from transcription 
factors such as yeast transcriptional activator GAL4 can be employed to 
attach a protein component to plasmid DNA [52]. Some DNA-binding 
proteins, such as the nuclear structural proteins histone H1, H3 or H4, 
have the ability to condense DNA [53]. However, most of these sequences 
are too long to be included in the peptide design. Detailed analysis of the 
sequences of DNA binding domains helps to identify short DNA binding 
motifs in the native DNA-binding proteins. For instance, the first 11 amino 
acids of polyomavirus structural proteins VP1 is able to bind to DNA 
without sequence specificity, and the first five amino acids appears to be 
crucial for binding [54]. DNA binding motifs derived from the C-terminus of 
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histone H1 are also shown to have DNA binding ability [55, 56]. Other than 
the above derivations, tandem repeats of positively-charged amino acids 
such as oligo-lysine and a sequence (YKAK8WK) analogous to spermine 
also have the capability to bind DNA efficiently [57-61]. 
 
Table 1.2.1 – Sequences of DNA binding and condensing domains. 
 





APKRKSGVSKC 11 54 
Histone H1 ATPKKSTKKTPKKAKK 16 55 
 KPSKKAKK 8 55 
 (SPKR)n 4n 56 
Oligo-lysine Kn n 57-60 
Spermine analogue YKAK8WK 13 61 
Note. Subscript n: integer number 
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1.2.4.2 Cell-targeting ligand 
For viral vectors, the cellular uptake is generally restricted by the native 
tropism of the original virus, whereas for non-viral vectors, the cellular 
uptake is mainly a random and non-specific process. To improve the 
cellular uptake, conjugation of cell-targeting ligand to a vector may 
increase the attachment to cell surface, which may be followed by 
receptor-mediated endocytosis. In the subsequent studies, it has become 
apparent that the addition of targeting ability has extended the application 
of gene therapy to many disease candidates. One obvious example comes 
from cancer gene therapy, in which the delivery of toxic genes is one of the 
most commonly used anti-tumor strategies. In this case, the expression of 
toxic genes should be restricted to the tumor cells only, while expression in 
any other non-tumor cells will have serious consequence. Tumor cell 
targeting ability is thus a critical element when designing a vector for 
treating tumors with metastasis. 
To retarget vectors to achieve site-specific delivery of the plasmid, 
various native ligands interacting with cell-surface receptors have been 
studied intensively. Ligands tested include asiaglycoprotein receptor, 
insulin, epidermal growth factor (EGF), galactose, transferrin, folate, lectins, 
and integrins [62-69]. However, association of multiple copies of native 
ligands could drastically alter the size and structure of the vectors. The 
possibility of evoking immunogenicity while using the native ligand domains 
is also a safety concern. Due to the potential problems mentioned above, 
the use of active sites or specific epitopes derived from native ligands is 
becoming popular. For instance, the Arg-Gly-Asp (RGD) sequence is found 
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in many extracellular matrix proteins related to cell adhesion, such as 
fibronectin and integrin. The RGD sequence has been shown to bind to 
integrins, a family of cell-surface proteins [70]. Other than sourcing from 
native ligands, it is also possible to develop a de novo ligand using the 
display systems. The principle underlying the display systems is the 
physical association of individual peptides or proteins with their 
corresponding genetic material. Several methods have been devised 
based on this principle, such as phage display, a cell-based system [71], 
and ribosome display, a cell-free system [72]. This technology helps to 
develop short cell-targeting ligands, which in turn provides more 
candidates for peptide design.  
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1.2.4.3 Cell-penetrating peptide 
The plasma membrane forms the first physical barrier for the transport 
of gene in the nucleus. It restricts passive diffusion of macromolecules and 
particles into the cells. Receptor-mediated endocytosis can facilitate the 
internalization of the complexes through the plasma membrane. To speed 
up the internalization process further, a group of short peptides, called cell-
penetrating peptides (CPPs), has been studied intensively during the last 
decades for their ability to translocate across the plasma membrane. The 
field started with discoveries in 1988 that the HIV-coded Tat regulatory 
protein could be taken up by cells when added to culture media, and in 
1991 that the homeodomain of Antennapedia (a Drosophila homeoprotein) 
was internalized by cells in a receptor-independent manner [73].  Studies 
using site-directed mutagenesis showed that the basic region (amino acids 
48-60) of Tat protein and the third helix (amino acids 43-58) of 
homeodomain of Antennapedia are necessary and sufficient for 
translocation [74, 75]. The initial studies showed that their mechanism of 
cellular entry appeared to be an energy-independent process since the 
internalization is faster than known endocytic processes and it can occur at 
low temperature (4°C) [75]. However, it was later demonstrated that this 
phenomenon could be due to the artefactual redistribution of CPPs and 
their associated cargos during the cell fixation for viewing of fluorophore-
labelled CPPs [76-78]. The binding of the highly cationic peptide to various 
anionic membrane components probably initiates the first step of the cell 
internalization process. Several studies also showed that the CPP 
mediated internalization is actually strongly dependent on the presence of 
 20 
chloroquine, which confirms the involvement of endocytosis pathway [79-
81]. 
Other than the homeodomain-derived peptides and Tat-derived 
peptides, signal-sequence-based peptides, transportan and amphiphilic 
model peptides are another three classes of CPPs [82-84]. Though the 
mechanism of cellular entry is far from being identified, the observed 
efficient in vitro and in vivo delivery of a large panel of different molecules 
(peptides, proteins, antisense oligonucleotides, antibiotics, PNA, drugs and 
fluorophores) after coupling to CPPs (either electrostatically or covalently) 
encourages their use in research [85-87]. 
 
Table 1.2.2 – Sequences of cell-penetrating peptides. 
 





RQIKIWFQNRRMKWKK 16 67 









Amphiphilic model peptide KLALKLALKALKAALKLA 18 77 
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1.2.4.4 Endosomolytic domain 
Following the internalization via adsorptive or receptor-mediated 
endocytosis, the complex containing vesicles fuse with early endosomes, 
which locate in periphery of cytoplasm with an acidic internal pH of about 
six. The early endosomes function as a sorting compartment, from where 
the internalized materials are redistributed. There are two possible 
outcomes for the internalized materials [88]. In recycling endosomes, the 
internalized materials are returned to the cell surface. Another possible fate 
is their transportation via late endosomes to lysosomes, in which the 
endocytosed materials are degraded by the action of acid hydrolases [89]. 
To avoid both of these two outcomes, the complex must be released from 
the endosome into the cytoplasm. The general strategy to achieve 
endosomolysis is to exploit endosomal acidification which is activated by 
the ATP-dependent proton pump on endosomal membranes [41]. 
Therefore, the endosomolytic peptides are usually amphipathic and 
sensitive to pH change within endosome. Membrane destabilization by 
endosomolytic peptides is assumed to occur by two mechanisms: 
membrane rupture and pore formation. Membrane rupture usually involves 
the alteration of the membrane properties while pore formation usually 
does not affect the general membrane properties [41].  
The most characterized endosomolytic peptides are derived from the 
N-terminal of the HA2 subunit of influenza hemaglutinin and are referred to 
as INF peptides [90]. At neutral pH (pH 7), these peptides adopt random 
coil structure due to the repulsion of the negatively charged glutamate and 
aspartate. As the pH decreases, the carboxyl groups of glutamate and 
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aspartate are protonated, followed by the transition of random coil structure 
into an amphipathic a-helical conformation with hydrophobic residues 
arranged on one side that may interact and destabilize the lipid bilayers. 
Based on the similar concept, amphipathic a-helical peptides with pH-
dependent lytic activities can be designed. For instance, a novel peptide 
JTS-1 can form pores on endosomal membrane at low pH since it contains 
hydrophobic face with only strongly apolar amino acids and hydrophilic 
face with glutamate residues [60]. When it is used in conjunction with a 
DNA condensing agent, high level of gene expression is observed in a 
variety of cell lines. A peptide GALA, based on the repeat unit Glu-Ala-Leu-
Ala, also exhibits the pH-dependent conformational transition [91, 92] but 
cannot bind to DNA directly for the strong negative charges on both GALA 
and DNA backbone repel each other [93]. A cationic peptide KALA, 
designed based upon GALA but containing a Lys-Ala-Leu-Ala, can interact 
with nucleic acids and perturb biomembranes at the same time [94].  
Instead of exploiting the protonation of the acidic amino acid residues 
(glutamate), it is possible to design another group of endosomolytic 
peptides based on the protonation of imidazole ring of histidine. Histidyl 
residues are expected to be protonated at a pH higher than glutamayl 
residues. Therefore, a properly designed histidine-rich peptide is expected 
to destabilize the endosomal membrane very early upon uptake [95]. For 
instance, the peptides H5WYG and LAH4 can insert into the endosomal 
membrane at pH 7, and upon acidification the polycationic species 
generated by the protonation of histidines cause membrane perturbation 
which leads to eventual leakage of the contents [95, 96]. Histidylated oligo- 
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and polylysine are also proved to enhance transfection efficiency 
compared to oligo- and polylysine [97, 98]. Another group of histidine-rich 
reducible polycations (HIS RPC) developed based on the partial “proton 
sponge” property of the histidyl residues are shown to be effective and 
versatile vectors [99].  
 
Table 1.2.3 – Sequences of endosomolytic domains. 
 
Name/source Sequence No of amino 
acids 
References 




















HIS6 RPC (CH6K3H6C)n 17n 92 
Note. Subscript n: integer number 
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1.2.4.5 Nuclear localization signal  
Transcription will only take place when the transgenes enter into the 
nucleus [100]. The nucleus of eukaryotic cells is protected by the nuclear 
envelope, which is also lipid bilayer like cell membrane. However, unlike the 
cell membrane, no evidence suggests a similar process like endocytosis to 
help the transport of materials into the nucleus. Hence, macromolecules are 
unable to diffuse through the nuclear membrane and the entry into the 
nucleus becomes a major limiting step. However, there are three possible 
pathways for the nuclear localization of transgenes: (1) DNA can pass through 
the nuclear pore complex (NPC), the only channel for the trafficking of 
macromolecules between the cytoplasm and the nucleus; (2) DNA can enter 
the nucleus during the breakdown and reformation of nuclear envelope in 
mitotic cells; or (3) DNA may traverse the nuclear envelope. Of these three 
possible routes, the second one may be quite widespread but limited to gene 
delivery application to the postmitotic and quiescent cells, whereas the third 
seems least likely and has no experimental support. The NPC is a large 
multiprotein structure which is composed of more than 100 proteins and 
polypeptides with an estimated aggregate mass of 125 MDa [41]. It spans 
across the nuclear envelop and extends into both cytoplasm and nucleoplasm. 
The NPC allows passive diffusion of small molecules with diameter up to 9 nm 
or 60 kDa, whereas larger molecules with diameter up to 10-25 nm or 1000 
kDa have to be actively transported [101, 102]. Therefore, passive diffusion of 
macromolecules does not occur and their selective entry into the nucleus 
through the active transport is facilitated by nuclear localization signal [103].  
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Studies on nuclear import proteins showed that the NLS are short amino 
acid sequences which can be recognized by cytoplasmic transport factors 
such as karyopherins or importins [41]. During nuclear transport, free 
cytoplasmic transport factors associate with the NLS to form a pore-targeting 
complex. The complex then docks on the cytoplasmic side of NPC followed by 
translocation through the pore in an energy-dependent process that is still not 
clearly understood. A large number of NLS sequences have been identified 
such as the monopartite NLS derived from the large tumor antigen of simian 
virus (SV40) and HIV-1 rev, as well as the bipartite NLS derived from 
nucleoplasmin [104-106].  Generally they contain one (monopartite) or two 
(bipartite) clusters of four or more basic amino acids (lysine or arginine) [101, 
103, 107].  Two strategies have been used to associate NLS to plasmid DNA. 
The first strategy involves the ionic interactions between the plasmid and the 
cationic NLS peptides while the second strategy involves covalent attachment 
of the NLS peptides to the plasmid. However, most of the experiments did not 
show that there is significant improvement in transgene expression by 
associating the NLS peptides to plasmid DNA [108, 109]. 
 
Table 1.2.4 – Sequences of nuclear localization signals. 
 
Name/source Sequence No of amino 
acids 
References 
SV40 T large antigen 
(126-132) 
PKKKRKV 7 97 
HIV-1 rev RRNRRRRW 8 98 
Nucleoplasmin KRPAAIKKAGQAKKKK 16 99 
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1.3 Aim of the Study 
The realization of gene therapy for various diseases depends on the 
introduction of therapeutic gene by the vectors into the disease cells. The 
major challenge of gene therapy research resides in the design of vectors 
that can overcome the low permeability of the cell membrane and improve 
intracellular trafficking and nuclear delivery of genes into target cells with 
minimal toxicity. While viral vectors remain as the most efficient carriers in 
vitro and in vivo, safety concerns arisen from their antigenicity have limited 
their clinical use. The non-viral vectors become attractive tools due to their 
simplicity of use and production as well as lower cytotoxicity. Among all the 
non-viral vectors, peptides appear to have a significant potential as 
commercially viable gene delivery products [41].   
In our studies, different peptide-based vectors were designed rationally 
for gene delivery. The similarity of these vectors is that they provide DNA 
binding and condensing ability as well as endosomolytic property. The 
characterization of DNA/peptide complexes was carried out by measuring 
their biophysical properties such as zeta potential and particle size. The 
transfection efficiency and cytotoxicity of these gene delivery vectors were 
evaluated by in vitro gene delivery in various cell lines.  
This study provides an example for using multi-domain 
peptide/polypeptide for gene delivery, and presents a platform for 
designing peptide-based vectors that are more efficient by including many 
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2 Material and Methods 
2.1 PEI600 Conjugated Synthetic Peptide and Histidine-
rich Peptides 
2.1.1 Conjugation of synthetic peptide to PEI600 
Tat peptide (GRKKRRQRRRQPPG) was synthesized in-house using a 
ResPep semi-automatic synthesizer (Intavis AG, Köln, Germany) according 
to a standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) protocol. The solid-
phase support used was Tentagel S Trt-Gly(Trt)Fmoc (0.23 mmol/g) 
purchased from Rapp Polymer (Tübingen, Germany). The use of this low-
substitution resin allows reduction in the density of produced peptide 
chains within the support matrix, thus decreasing the chance for one 
PEI600 molecule to interact with multiple peptides. Immediately after the 
peptide synthesis, the end amino groups of the peptides were activated for 
1 hour on the resin support in a synthesis column by disuccinimidyl 
carbonate (DSC), a cross-linking reagent that can react with two amine 
groups in nonaqueous environment. After washing the column to remove 
excess DSC, the activated peptides were mixed with a large excess of 
PEI600 (number average molecular weight Mn = 600 and weight average 
molecular weight Mw = 800, Sigma-Aldrich, CA, USA), and the two 
compounds were allowed to react for 5 hours. The column was washed 
again to remove free PEI600. The peptides were then deprotected, cleaved 
from the resin and precipitated with ether. After dialysis using Spectrapor™ 
7 dialysis membrane with a molecular weight cutoff of 2 kDa against 
distilled water, the precipitate was freeze-dried.  
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2.1.2 Synthesis of histidine-rich peptides 
All the histidine-rich peptides were chemically synthesized and purified 
by GL Biochem Ltd. (Shanghai, China). They were provided in dry powder 
which was resuspended in Milli-Q water (Millipore, Massachusetts, USA) to 
a concentration of 1 mM and kept in aliquots at -20°C. 
 
2.1.3 1H-NMR and gel permeation chromatography (GPC) 
Tat-PEI600 conjugates were characterized by 1H-NMR and GPC 
analysis. Proton nuclear magnetic resonance (1H NMR) spectroscopy is a 
powerful method used in the determination of the structure of unknown 
organic compounds. The 1H-NMR analysis was carried out with 2 mg/ml 
solution of Tat-PEI600 conjugate sample dissolved into deuterium oxide 
(D2O) in Bruker 400 MHz NMR Spectrometer with 32 scans at room 
temperature. Gel permeation chromatography is used to analyze the 
molecular weight distribution of organic-soluble polymers. GPC analysis was 
carried out on a Shimadzu 10AVP liquid chromatography system with a 
Refractive Index Detector. The temperature was fixed at 40°C. Typically, a 
volume of 50 ml of the sample was injected in Shodex OHpack SB-803 HQ 
column. The flowrate was 1 ml/min using acetate buffer as the mobile phase. 
A molecular weight standard curve was made using seven poly(ethylene 
glycol) polymer with Mn ranging from 200- 40,000 Da. 
 
2.1.4 Preparation and characterization of DNA complexes 
To prepare DNA complexes, Tat-PEI conjugate or peptides were 
added dropwise into a 5% glucose solution at pH 7 containing a plasmid 
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vector encoding a firefly luciferase gene (pCAG-luc, kindly provided by 
Yoshiharu Matsuura, National Institute of Infectious Diseases, Tokyo, 
Japan) or a plasmid DNA encoding a GFP gene [110] while vortexing. In 
the preparation of the ternary complex, PEI600 and Tat peptide were 
sequentially added to DNA. DNA was first mixed with PEI600 first at 
designated N/P ratio, waited for 30 min and followed by addition of various 
amounts of Tat peptides. In the case of preparing the complex with 
bis(cysteinyl) histidine-rich peptide, peptide was allowed to bind to DNA for 
30 min to form a stable complex. Following that, the complex was shaken 
at 600 rpm for 1.5 hours at room temperature to allow interpeptide disulfide 
bond formation by air oxidation. 
A common technique used to study DNA/peptide interaction is agarose 
gel retardation assays. This procedure can determine if a peptide is 
capable of binding to DNA. Twenty five ml of complex solution was mixed 
with 5 ml of 6× loading buffer and loaded onto an EtBr containing 1% Tris-
borate-EDTA (TBE) agarose gel. Electrophoresis was carried out at a 
voltage of 80 V (Bio-Rad Power Pac 200, CA, USA) for 45 minutes in TBE 
running buffer solution. UV light (254 nm) detection was conducted with 
Fluorchem™ from Alpha Innotech. For particle size and zeta potential 
measurement, DNA complexes in 5% glucose were prepared at a DNA 
concentration of 5 mg/ml. Particle sizes were determined by dynamic light 
scattering, and zeta potentials were measured electrophoretically using 
Zetasizer Nano-ZS (Malvern Instruments, MA, USA). 
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2.1.5 Cell cultures, transfection and luciferase activity assays 
Human glioma cell lines U251, H4, T98G and rat glioma cell line C6 
were grown in DMEM supplemented with 10% fetal bovine serum, penicillin 
and streptomycin. The cells were maintained in a humidified incubator with 
5% CO2 at 37°C. Cells were grown to 50-70% confluency in either 48-well 
plates for luciferase activity assay or 96-well plates for GFP expression 
analysis. Transfections were performed with DNA complexes in Opti-MEM. 
For some experiments, Opti-MEM was added with 100 mM chloroquine or 
200 nM bafilomycin A1. After  4 hours incubation at 37°C, each well was 
topped up with DMEM supplemented with 10% FBS. For luciferase activity 
assays, cells were washed one day later with phosphate buffer saline (PBS) 
and permeabilized with a reporter cell lysis buffer (Promega, WI, USA). 
Ten ml of the cell extract was used for luciferase assays with an assay kit 
from Promega. Measurements were made in a single-tube luminometer 
(Berthold Lumat LB 9507, Bad Wildbad, Germany) for 10 sec. Results are 
expressed in relative light units (RLU) per mg total protein. The data are 
presented as means with SD (n=4).  
In experiments using a GFP plasmid [110], transfection was 
determined in quadruplicates 2 days later by fluorescence microscopy of 
GFP-positive cells in comparison to the total number of cells counted by 




2.1.6 Cytotoxicity assay 
U251 cells were allowed to attach in 96-well microplates overnight and 
then incubated with a range of concentrations of different testing materials. 
After 4 hours incubation at 37°C, each well was topped up with DMEM 
supplemented with 10% fetal bovine serum. After 20 hours, 20 ml of a 
proliferation assay solution (CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay, Promega) was added to each well, followed by 3 hours 
of incubation at 37°C in a humidified incubator with 5% CO2. After the 
incubation period, the plate was transferred to a microplate reader (Bio-
Rad) to measure the absorbance at a wavelength of 490 nm. Quintuplicate 
determinations for each treatment were performed. The relative cell growth 
(%) related to control cells cultured in media was calculated by 
(absorbance of sample – absorbance of blank) / (absorbance of control – 





2.2  Bacterially Produced Polypeptide 
2.2.1 Plasmid construction 
By a PCR-mediated gene assembly method [111], a DNA fragment 
encoding (SPKR)4 and the a-helical linker, TYLSEDELKAAEAAFKRHNPT, 
was first constructed and cloned into the pET-16b expression vector 
(Novagen, WI, USA) between the Nde I and Bam HI sites, downstream of a 
His10 tag, to create pET16-(SPKR)4linker. The DNA sequence encoding full 
length BDNF was first cloned into a TA vector by PCR amplification of 
human brain cDNA (Clontech, Palo Alto, CA, USA). The DNA sequence 
corresponding to amino acids 22-74 of BDNF was amplified with the 
forward primer (5’-CTGGATCCTG CAGTATTAGT GAGAGTGGGT AAC-3’) 
and the reverse primer (5’-ATGGATCCTC AGCCTTCTTT TGTGTAACC-
3’). These primers introduced BamHI restriction sites at both ends to 
enable the digested fragment to be ligated in frame with the a-helical linker 
sequence. In addition, the forward primer introduced an additional Cys 
codon. The construct, designated pET16-(SPKR)4BL-1,2, was checked for 
correct insert orientation and sequenced by conventional methods. 
 
2.2.2 Polypeptide expression, purification and detection 
For polypeptide expression, the E. coli strain BL21(DE3)pLysS 
(Novagen, WI, USA) bearing pET16-(SPKR)4BL-1,2 was vigorously shaken 
at 37°C in LB medium containing 50 mg/ml of ampicillin and 34 mg/ml of 
chloramphenicol until the optical density reached 0.7. Expression of the 
polypeptide was then induced at 30°C by the addition of 1 mM isopropyl-b-
d-thiogalactopyranoside (IPTG, Bio-Rad, CA, USA). The bacteria was 
 34 
harvested by centrifugation 90 min later and frozen. The cell pellet was 
resuspended in cold lysis buffer (50 mM sodium phosphate, 1 M NaCl, 10 
mM imidazole, 0.1% Triton X-100, pH8.0) supplemented with EDTA-free 
protease inhibitor (Calbiochem, CA, USA). The cell lysate was sonicated 
until no longer viscous and cleared by centrifugation. The supernatant was 
purified by nickel-chelate affinity chromatography on an ÄKTAexplorer 
FPLC (Amersham Biosciences, Uppsala, Sweden). A 4 ml HisTrap column 
(Amersham Biosciences) equilibrated with lysis buffer was used to purify 
lysate from 1.6 liter of culture; washing and eluting was performed by 
increasing the imidazole concentration. The eluted fractions were analyzed 
by SDS gel electrophoresis and Western blotting using antibodies against 
His-tag (Qiagen, Hilden, Germany). Approximately 4 to 6 mg of polypeptide 
was expressed per liter of the culture, giving a typical yield of 1 mg per liter 
of culture after purification. The fractions containing the purified 
polypeptide were pooled and dialyzed against distilled water at 4°C. 
 
2.2.3 Preparation and characterization of DNA complexes 
2.2.3.1 Preparation of DNA complexes 
The firefly luciferase reporter plasmid used was pCAG-luc (kindly 
donated by Yoshiharu Matsuura, National Institute of Infectious Diseases, 
Tokyo, Japan), with a composite promoter CAG consisting of the 
cytomegalovirus immediate-early enhancer, chicken b-actin promoter and 
rabbit b-globin polyadenylation signal. The quantity and quality of the 
purified plasmid DNA was assessed by its optical density at 260 and 280 
nm and by electrophoresis in 1% agarose gel. The purified plasmid DNA 
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was re-suspended in TE buffer and kept in aliquots at a concentration of 2 
mg/ml.  
The plasmid was complexed with the polypeptide or polyethylenimine 
(PEI600 with MW=600 and PEI25kDa with MW=25,000, Sigma-Aldrich) for 
gene transfection. To form triplexes, plasmid in 5% (w/v) glucose and 
polypeptide were first mixed and incubated for 30 min at room temperature, 
after which PEI600 was added and the mixture incubated for a further 30 
min before use. The required amount of PEI600 was calculated based on 
the nitrogen/phosphate ratio used and by taking into account that 1 µg of 
DNA contains 3 nmol of phosphate. 
 
2.2.3.2 DNA retardation assay 
A DNA retardation assay was carried out to qualitatively assess the 
ability of (SPKR)4BL-1,2 to bind to DNA and thus to retard its migration (by 
decreasing its charge/mass ratio) through an agarose gel under 
electrophoresis. Various amounts of the protein were added to 0.1 mg of 
plasmid DNA made up to 20 ml with 5% glucose. The mixtures were 
vortexed and incubated at room temperature for 30 min before being 
subjected to electrophoresis in a 1.0% Tris-borate-EDTA (TBE) agarose 
gel stained with ethidium bromide for visualization under ultraviolet light. 
 
2.2.3.3 Topology of the plasmid, polypeptide and DNA complex 
The topologies of DNA samples, (SPKR)4BL-1,2, as well as 
DNA/(SPKR)4BL-1,2 complexes were examined by atomic force 
microscopy (AFM). Naked plasmid DNA was diluted in HEPES-Mg buffer 
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(10 mM MgCl2, 40 mM HEPES, pH 7.6) to a final concentration of 30 ng/ml. 
After incubation for 5-10 min at room temperature, 2 ml of the solution was 
deposited onto the center of a freshly cleaved mica surface. After being left 
to stand for 10 min, the sample was rinsed with 2-5 ml of deionized water. 
The sample was then blown dry with a gentle stream of nitrogen. 
(SPKR)4BL-1,2 and DNA/(SPKR)4BL-1,2 complexes with N/P ratio of 10:1 
were diluted with deionized water. After incubation for 30 min at room 
temperature, 3 ml of each aqueous complex solution (with final DNA 
amounts of 10 ng in each sample) was deposited onto mica, rinsed, and 
dried as described above. AFM (Multi Mode, Nanoscope III, Digital 
Instruments, Santa Barbara, CA) was used to obtain images at room 
temperature in tapping mode using Nanoprobe Silicon tips (Digital 
Instruments, Woodbury, NY, USA) with a spring constant of 34 N/m and a 
resonance frequency of about 280 kHz. Scanning was performed at a scan 
speed of 0.5-2 Hz. The 256×256 pixel images were captured with scan size 
of 1-2 mm. The tip loading force was minimized to avoid structural changes 
to the samples. 
 
2.2.4 Cell cultures 
Primary cultures of neurons were established from the cortices of 
embryonic Wistar rats at gestational day 15. Cortices free of meninges 
were dissected and individual cells were dispersed mechanically by 
trituration of minced tissue in 3 ml DMEM medium supplemented with 2% 
FBS. The suspension was allowed to settle in a centrifuge tube. The cells 
in the supernatant were collected by centrifugation and resuspended gently 
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in DMEM with 10% FBS. Viability of the cells was assessed prior to plating 
using trypan blue. Cells were plated onto microplates pre-coated with poly-
L-lysine/laminin at a density of 7.5×105 viable cells/cm2. After a 2 hours 
incubation period to allow neurons to attach, the medium and unattached 
cells were removed and replaced by serum-free DMEM/F12 medium with 
1% N2 supplement (Invitrogen, CA, USA). The cells were then incubated at 
37°C in 5% CO2 in a humidified incubator. After 2-5 days of culture, the 
neuron cells were used for transfection experiments. 
Primary cultures of glial cells were also established from the cortices of 
20-day old embryonic Wistar rats. Individual cells were collected as 
described above. The cells were plated at a density of 4×105 viable 
cells/cm2 on poly-L-lysine/laminin coated dishes and grown to confluence 
for 7 days in DMEM/F12 medium supplemented with 10% FCS. The day 
before transfection, the cells were detached and plated into coated 
microplates at a density of 2.5×104 cells per well. 
All the cell lines were obtained from ATCC (American Type Culture 
Collection, VA, USA). Rat PC-12 pheochromocytoma cells were grown in 
RPMI-1640 medium supplemented with 10% fetal bovine serum (Sigma-
Aldrich, MO, USA) and 5% horse serum (Sigma-Aldrich, MO, USA). PC-12 
cells are known to express TrkA and p75 receptors. NIH-3T3 cells and 
HeLa cells were grown in DMEM (Sigma-Aldrich, MO, USA) supplemented 
with 10% fetal bovine serum (Sigma-Aldrich, MO, USA). The cells were 
maintained in a humidified incubator with 5% CO2 at 37°C. The cells were 
grown to 50-70% confluency in 48-well microplate, followed by the 
 38 
replacement of cell culture medium to serum-free medium before any 
experiments were carried out. 
 
2.2.5 In vitro gene transfer 
The gene delivery complexes were prepared according to the 
specifications presented for each experiment. The complexes were then 
added and incubated with cells in a humidified incubator for 4 hours. In 
receptor blocking assay, the cells were preincubated with antibody anti-p75 
specific against rat p75 receptors (1:100 dilution, Chemicon, CA, USA) for 
1 hour before addition of the complex. In competition binding assay, 20 
ng/ml of NGF (Invitrogen, CA, USA) or 500 ng/ml of BDNF (Invitrogen, CA, 
USA) was added together with the complexes. After the incubation in 
normal culture medium for another 20 hours, cells were washed and 
permeabilized with the reporter cell lysis buffer (Promega, WI, USA). The 
luciferase activity in cell extracts was measured using a luciferase assay kit 
(Promega, WI, USA). Each measurement was carried out for 10 seconds in 
a single-well luminometer (Berthold Lumat LB 9507, Bad Wildbad, 
Germany). The relative light units (RLU) were normalized by the total 
protein concentration of the cell extracts, measured with DC Protein Assay 
































3.1 Studies Using PEI600 Conjugated Synthetic Peptide 
3.1.1 Characterization and in vitro transfection efficiency of 
DNA/PEI600/Tat peptide ternary complex 
To prepare ternary complex composed of DNA, PEI600 and Tat 
peptides, DNA was first mixed with PEI600 at a N/P ratio of 1, complex 
was incubated for 30 min, and then various amounts of Tat peptide was 
added. In DNA retardation assay, the DNA mobility through an agarose gel 
during electrophoresis was significantly reduced when the N/P ratio of the 
ternary complex reached 5 (Fig 3.1.1A).  
Chloroquine is known to block endosomal acidification and induce 
osmotic swellings of the endosomes leading to membrane rupture. To 
investigate whether PEI600 was able to improve Tat peptide-mediated 
gene delivery as chloroquine does, in vitro transfection experiments were 
carried out in U251 cells with DNA/Tat peptide complexes, in the presence 
or absence of PEI600 or 100 mM of chloroquine. At low N/P ratios, Tat 
peptides had no transfection activities, and adding chloroquine to the 
medium or PEI600 to the DNA/Tat peptide complexes did not improve 
transfection either (Fig 3.1.1B). At higher N/P ratios, PEI600 could improve 
Tat transfection activity as effectively as chloroquine, resulting in more than 
3- and 6-fold increase of luciferase expression at the N/P ratios of 5 and 10, 
respectively (Fig 3.1.1B). The stability of the ternary complexes was 
determined by measuring the change in size and zeta potential of the 
complexes over time. The size and zeta potential of the ternary complexes 
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increased and decreased, respectively, over time, which suggested that 
the ternary complexes were unstable (Table 3.1.1). 
 
Table 3.1.1 – Biophysical properties of DNA/PEI600 and DNA/PEI600/Tat 
complexes.  
The complexes were prepared with an N/P ratio of 10 in 5% glucose solution 
at pH 7. Each experimental result represents the mean ± SD, n=3. t=0 refers 
to the time point after 30 min incubation for stabilization of the complexes. 
 
Zeta potential (mV) Size (nm) 
DNA Complex 
t=0 t=2hr t=0 t=2hr 
DNA/PEI600 23±2 13±1 *** 101±4 142±4 *** 
DNA/PEI600/Tat 27±5 14±8 * 130±17 244±22 ** 








Fig 3.1.1 – Chloroquine and PEI600 improve Tat-mediated gene transfection. 
(A) Agarose electrophoresis was carried out for pCAG-luc DNA complexed 
with a mixture of PEI600 and Tat peptides at an N/P ratio from 0 to 10. M: 
DNA marker lane.  
(B) Comparison of gene transfection efficiencies in U251 cells. pCAG-luc 
complex with Tat peptides (Tat), PEI600, Tat peptides in the presence of 100 
mM of chloroquine (Tat+Chlor), and Tat peptides together with PEI600 
(Tat+PEI600). Values are expressed as relative light units (RLU) per milligram 




3.1.2 Synthesis and characterization of Tat-PEI600 conjugate 
To increase the stability of ternary complex DNA/PEI600/Tat peptide, a 
solid-phase chemical synthetic method was developed to synthesize a 
peptide-polymer hybrid. Right after solid-phase Tat peptide synthesis, the 
amine group of the last glycine residue of Tat peptide was activated by 
disuccinimidyl carbonate (DSC) on the resin support when the side chains 
of other peptide residues were still protected. The activated glycine was 
then linked with an amine group of PEI600 by amide bond formation (Fig 
3.1.2A). The conjugation of PEI600 to the Tat peptide was characterized by 
1H-NMR spectroscopy and the conjugation ratio was estimated by proton 
integration. Comparing the 1H-NMR spectra of a PEI600/Tat peptide 
mixture and Tat-PEI600 conjugates, the multiple peaks from PEI were 
found to shift from 1.2-2.5 in the mixture to 2.5-3.2 ppm in the conjugates 
(data not shown), indicating the formation of the covalent bond between 
PEI600 and the Tat peptide. The ratio of the Tat peptide to PEI600 in the 
conjugate was determined from 1H NMR spectroscopy by integrating the 
peaks of -CH2- and -aCH2- protons of the peptide (1.1-2.4 and 3.3-4.3 ppm 
respectively) and -CH2CH2NH- protons of PEI (2.5-3.2 ppm). The Tat 
peptide contains 36 CH2 groups from arginine, lysine, glutamine and 
proline and 2 aCH2 groups from glycine (76 protons in total), while, on 
average, a single molecule of PEI600 contains 19 groups of CH2CH2NH 
with 4 protons each. Based on the integral values in Fig 3.1.2B, 4.2% of the 
CH2CH2NH groups in the PEI600 polymer were modified during the 
conjugation, corresponding to one molecule of PEI600 being attached to a 
single molecule of the Tat peptide. Gel permeation chromatography (GPC) 
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analysis was also carried out to determine the molecular weight of the Tat-
PEI600 conjugate. The theoretical molecule weight of the conjugate with a 
1:1 ratio would be 2500 g/mol. GPC analysis revealed a molecule weight of 
2300 g/mol, implying again that one molecule of PEI600 was conjugated to 
a single Tat peptide. 
 
 
Fig 3.1.2 – Tat-PEI600 conjugation.  
(A) Chemical structure of PEI600 conjugated to Tat peptide through the 
formation of an amide bond.  
(B) Proton NMR chromatogram of PEI600 conjugated to Tat peptide. 
Tat-PEI600 conjugate 
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3.1.3 Characterization and in vitro transfection efficiency of 
DNA/Tat-PEI600 complexes 
The Tat-PEI600 conjugates could bind to and fully condense plasmid 
DNA, as demonstrated in a DNA retardation assay and particle size 
measurement (Fig 3.1.3A and Table 3.1.2). The biophysical parameters of 
the DNA/Tat-PEI600 complexes were similar to those of DNA complexes 
compacted with PEI25kDa, the gold standard for nonviral gene carriers 
(Table 3.1.2).  
 
 
Table 3.1.2 – Biophysical properties of DNA/Tat-PEI600 conjugate and 
DNA/PEI25 complexes.  
The complexes were prepared with an N/P ratio of 10 in 5% glucose solution 
at pH 7. Each experimental result represents the mean ± SD, n=3. t=0 refers 
to the time point after 30 min incubation for stabilization of the complexes. 
 
Zeta potential (mV) Size (nm) 
DNA Complex 
t=0 t=2hr t=0 t=2hr 
DNA/Tat-PEI600  25±2 26±3 113±5            126±5 




The transfection efficiencies of these DNA complexes were compared 
in U251 and H4 cells. The Tat-PEI600 conjugates mediated gene transfer 
dose-dependently (Fig 3.1.3B). At a higher N/P ratio of 10 or 20, the 
conjugates displayed a striking advantage over non-conjugated PEI600 
and Tat peptides, providing up to 37-fold higher transgene-expression 
levels in U251 and H4 cells (Fig 3.1.3B). These levels of gene expression 
were close to that afforded by PEI25kDa. Further transfection experiments 
using a GFP reporter gene were carried out and the number of GFP-
positive cells was counted under a fluorescence microscope. Using 
noncovalent ternary complexes to transfect U251 cells, only few GFP-
positive cells per well in a 96-well plate was observed. The number of 
GFP-positive cells increased significantly to about 100 per well after 
transfection with either DNA/Tat-P600 complexes or DNA/PEI25kDa 
complexes (Fig 3.1.3C). The percentage of GFP-positive cells was 1.66% ± 
0.21 and 1.41% ± 0.24 (mean ± SD, n=4) in the Tat-PEI600 and PEI25kDa 




Fig 3.1.3 – Covalent attachment of PEI600 improves Tat-mediated gene 
transfection.  
(A) Agarose electrophoresis was carried out for pCAG-luc DNA complexed 
with Tat-PEI600 conjugates at an N/P ratio from 0 to 10. M: DNA marker 
lane.  
(B) Comparison of gene transfection efficiencies between DNA/PEI600/Tat 
ternary complexes (P600+Tat) and DNA/Tat-PEI600 conjugate complexes 
(Tat-P600) in U251 and H4 cells using a luciferase reporter gene. DNA 
complexed with PEI25kDa (PEI25) at an N/P ratio of 10 was used as a 
positive control. Values are expressed as RLU per mg total protein and the 
SD is indicated with error bars (n=4).  
(C) Fluorescence microscopic images of U251 cells transfected with 
PEI25/GFP plasmid and Tat-P600/GFP plasmid complexes. Scale bars: 
100 mm. 





3.1.4 Cytotoxicity of Tat-PEI600 conjugate 
The cytotoxicity caused by these gene delivery vectors was evaluated 
in U251 cells. U251 cells were exposed to various concentrations of the 
materials for 24 hours. The cell viability assay indicated that PEI600, Tat 
peptides and Tat-PEI600 conjugates display no cytotoxicity in these cells at 
concentrations up to 2 mM. This was remarkably different from the test with 
PEI25kDa, which caused obvious cell death at 250 nM and almost 100% 
cell death at 2 mM (Fig 3.1.4). These results suggested that the peptide-
polymer hybrid vector maintains the desirable property of low cytotoxicity 




Fig 3.1.4 – Cytotoxicity of Tat-PEI600 conjugate in U251 cells.  
The cells were treated with various concentrations of materials for 24 hr. 
Cell viability was determined and expressed as percentage of control, i.e. 
the untreated cultures (mean ± SD, n=5). 
Tat-P600 
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3.2 Studies Using Histidine-rich Synthetic Peptides 
3.2.1 Characterization of DNA/histidine-rich peptide 
complexes 
To compare the DNA binding ability of histidine-rich peptides, DNA 
retardation assay was performed with DNA/peptide complexes prepared at 
different N/P ratios. Fig 3.2.1 shows that the mobility of plasmid DNA was 
reduced with increasing peptide concentration, indicating complete charge 
neutralization of DNA. Consistent with this result, the zeta potential 
measurements showed that all the complexes at N/P ratios of 5, 10 and 20 
are positively-charged. The particle sizes of the complexes lie between 80-
140 nm. Both zeta potential and particle size measurements stayed very 
similar over time (Table 3.2.1).  
 
Table 3.2.1 – Biophysical properties of DNA/histidine-rich peptide complexes.  
The complexes were prepared in 5% glucose solution at pH 7. Each 
experimental result represents the mean ± SD, n=4. t=0 refers to the time 
point after 30 min incubation for stabilization of the complexes. 
 
Zeta potential (mV) Size (nm) 
DNA Complex N/P ratio 
t=0 t=2hr t=0 t=2hr 
5 34±2 37±1 99±3 96±2 
10 32±1 34±1 95±3 115±1 DNA/H10K2(SPKR)4 
20 28±2 31±1 102±8 105±10 
5 28±2 31±1 102±8 105±10 
10 30±1 27±4 131±1 137±5 DNA/10K-10H 
20 29±2 31±1 121±11 141±19 
5 30±1 31±1 89±2 102±2 
10 29±1 32±4 120±3 113±5 DNA/Tat-10H 





















Fig 3.2.1 – DNA retardation by histidine-rich peptides. 
Agarose electrophoresis was carried out for pCAG-luc DNA complexed with 







 M    0     2     4     6     8    10   15 N/P 
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3.2.2 Comparison of transfection efficiencies of 
DNA/histidine-rich peptide complexes 
The transfection efficiencies of DNA/histidine-rich peptide complexes 
were compared in human glioma cell lines U251 and H4. All the histidine-
rich peptides mediated gene transfer dose-dependently (Fig 3.2.2). At N/P 
ratio of 10, the Tat-10H peptide was superior to the other two peptides 
H10K2(SPKR)4 and 10K-10H, providing up to 385-fold higher transgene-
expression levels in U251 and H4 cells. Particularly in H4 cells, the 
transfection efficiency of Tat-10H peptide at N/P ratio of 10 was 























Fig 3.2.2 – Comparison of transgene expression mediated by histidine-rich 
peptides in U251 and H4 cells.  
DNA complexed with PEI25kDa (PEI25) at N/P ratio of 5 and 10 were used 
as positive control. Values are expressed as RLU per mg total protein and 
the SD is indicated with error bars (n=3). 
*** p<0.001, ** p<0.005, * p<0.05 
PEI25 H10K2(SPKR)4 10K-10H Tat-10H 
U251 







3.2.3 Covalent linkage between Tat and oligohistidine 
sequence 
To investigate the importance of covalent linkage between Tat and 
oligohistidine (10H), the transfection was carried out in U251 cells with 
three different DNA/peptide complexes: (1) DNA/Tat peptide; (2) 
DNA/mixture of Tat peptide and 10H peptide; and (3) DNA/Tat-10H peptide. 
Tat peptides had no transfection activities, and adding 10H peptide to the 
DNA/Tat peptide complexes did not improve transfection either (Fig 3.2.3). 
However, the Tat-10H peptide (covalently-linked Tat peptide and 10H 
peptide) showed up to 7000-fold improvement in terms of transfection 













Fig 3.2.3 – Covalent linkage between Tat and oligohistidine improves gene 
expression.  
DNA complexed with PEI25kDa (PEI25) at an N/P ratio of 5 was used as a 
positive control. Values are expressed as RLU per mg total protein and the 
SD is indicated with error bars (n=3). * p<0.001 
* * U251 
PEI25 Tat Tat/10H Tat-10H 
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3.2.4 Endosomolytic property of oligohistidine sequence 
To investigate influence of endosomal pH on the transfection efficiency 
of Tat-10H, the transfection was carried out in U251 cells in the presence 
of bafilomycin A1.  Bafilomycin A1 is an inhibitor of vacuolar H+-ATPases 
which will stop the proton influx into endosomes. The results showed that 
co-incubation with bafilomycin A1 has reduced the transfection efficiency of 
Tat-10H peptide significantly (Fig 3.2.4A). 
To optimize the number of histidine residues for endosomolysis, Tat 
peptides covalently linked with different numbers of histidine residues, 
namely Tat-5H, Tat-10H and Tat-20H, were tested in U251 cells. Tat-5H 
peptide can mediate gene delivery dose-dependently but the transfection 
efficiency was lower than that of Tat-10H (Fig 3.2.4B). On the other hand, 
although Tat-20H peptide was designed to have more histidine residues for 
more efficient endosomolysis, it was less efficient than Tat-10H peptide, 























Fig 3.2.4 – Endosomolytic property of oligohistidine in Tat-10H peptide.  
DNA complexed with PEI25kDa (PEI25) at an N/P ratio of 5 was used as a 
positive control. Values are expressed as RLU per mg total protein and the 
SD is indicated with error bars (n=3). ** p<0.001, * p<0.05 
(A) U251 cells were co-incubated with 200 nM bafilomycin A1 (BA1) during 
transfection with DNA/Tat-10H peptide complexes at N/P ratios of 10 and 20. 
(B) Transfection efficiencies of Tat peptides covalently linked with different 




PEI25 Tat-10H Tat-10H + BA1 
** 
U251 
** ** ** 




3.2.5 Characterization of DNA/bis(cysteinyl) histidine-rich 
peptide complexes 
A bis(cysteinyl) histidine-rich peptide, C-5H-Tat-5H-C, was designed to 
further improve the stability of DNA condensate for in vivo application. The 
counterpart peptide which does not have the cysteine residues, 5H-Tat-5H, 
served as a control. To compare the DNA binding ability, DNA retardation 
assay was performed with DNA/peptide complexes prepared at different 
N/P ratios. Fig 3.2.5 shows that the complex prepared at N/P ratio of two 
was immobilized, indicating complete charge neutralization of DNA. 
Consistent with this result, the zeta potential measurements showed that 
the complexes at N/P ratios of 5, 10 and 20 are positively-charged. The 
particle sizes of the complexes lie between 90-170 nm. Both zeta potential 
and particle size measurements were very similar over time, except that of 
the DNA/5H-Tat-5H complex prepared at N/P ratio of 5 (Table 3.2.2). 
 
Table 3.2.2 – Biophysical properties of DNA/C-5H-Tat-5H-C peptide and 
DNA/5H-Tat-5H peptide complexes.  
The complexes were prepared in 5% glucose solution at pH 7. Each 
experimental result represents the mean ± SD, n=4.  t=0 refers to the time 
point after 30 min incubation for stabilization of the complexes. 
 
Zeta potential (mV) Size (nm) 
DNA Complex N/P ratio t=0 t=2hr t=0 t=2hr 
5 31±1 32±1 92±1 94±1 
10 36±1 39±1 111±2 102±1 DNA/C-5H-Tat-5H-C 
20 35±2 37±1 149±2 148±3 
5 29±3 18±1 192±8 191±1 
10 35±1 36±1 112±3 99±1 DNA/5H-Tat-5H 



















Fig 3.2.5 – DNA retardation by bis(cysteinyl) histidine-rich peptide and the 
counterpart without cysteine residues.  
Agarose electrophoresis of pCAG-luc DNA complexed C-5H-Tat-5H-C or   
5H-Tat-5H at an N/P ratio from 0 to 15. M: DNA marker lane. 




3.2.6 Interpeptide disulfide bond formation of bis(cysteinyl) 
histidine-rich peptide 
To evaluate the effect of incubation time on interpeptide disulfide bond 
formation, DNA was complexed with the bis(cysteinyl) histidine-rich peptide 
at different N/P ratios, incubated for different time duration. The control 
group was incubated for 30 min at room temperature to form stable 
complex. And the test group was first incubated for 30 min, followed by 
another 1.5 hr shaking incubation at room temperature to facilitate disulfide 
bond formation by air oxidation. The transfection efficiencies were 
compared in human glioma cell lines U251. The control group gave similar 
transgene expression for all N/P ratios (Fig 3.2.6A). However, the test 
group displayed a different transgene expression profile. The transfection 
efficiency decreased with increasing N/P ratios. The maximum transfection 
efficiency of test group was achieved at N/P ratio of 3, providing up to 5-
fold higher transgene expression level than that afforded by the control 
group at N/P ratio of 20 (Fig 3.2.6A). The biophysical properties of 
DNA/peptide complex prepared at N/P ratio of 3 was measured to check 
the change in particle size and zeta potential after shaking incubation. The 




Table 3.2.3 – Biophysical properties of DNA/C-5H-Tat-5H-C peptide 
complexes after incubation for different time duration.  
The complexes were prepared at an N/P ratio of 3 in 5% glucose solution at 
pH 7. Each experimental result represents the mean ± SD, n=4. 
 
Incubation time Size (nm) Zeta potential (mV) 
30 min 127±10            32±1 
2 hr with shaking 100±2 * 36±1 
* p<0.005 (when compared with the value of 30 min incubation). 
  
 
The role of interpeptide disulfide bond formation was investigated by 
comparing the transfection efficiency of bis(cysteinyl) histidine-rich peptide 
(C-5H-Tat-5H-C peptide) with its counterpart without the cysteine residues 
(5H-Tat-5H peptide). Prior to transfection, the DNA/C-5H-Tat-5H-C peptide 
complex was incubated for 2 hr with shaking and the DNA/5H-Tat-5H 
peptide complex was incubated for 30 min. The 5H-Tat-5H peptide 
mediated gene transfer dose-dependently, but the maximum transfection 
efficiency achieved was 140-fold lower than that afforded by the C-5H-Tat-






















Fig 3.2.6 – Interpeptide disulfide bond formation improves transfection 
efficiency.  
DNA complexed with PEI25kDa (PEI25) at an N/P ratio of 5 was used as a 
positive control. Values are expressed as RLU per mg total protein and the 
SD is indicated with error bars (n=3). ** p<0.005, * p<0.01 
(A) U251 cells were transfected by DNA/C-5H-Tat-5H-C peptide complexes 
incubated for 30 min and 2 hr. 
(B) Transfection efficiencies of C-5H-Tat-5H-C was compared with 5H-Tat-5H 
at different N/P ratios in U251 cells.  
 










The transfection efficiency of C-5H-Tat-5H-C peptide was also 
compared to that of original design Tat-10H peptide in different glioma cell 
lines. In the transfection experiments using a luciferase reporter gene, the 
bis(cysteinyl) histidine-rich peptide was statistically more efficient than the 
original design in three out of four glioma cell lines (Fig 3.2.7). Further 
transfection experiments using a GFP reporter gene also showed that the 
bis(cysteinyl) histidine-rich peptide can transfect more cells than the 













Fig 3.2.7 – Comparison of transfection efficiencies between C-5H-Tat-5H-C 
and Tat-10H in different glioma cell lines.  
DNA complexed with PEI25kDa (PEI25) at an N/P ratio of 5 was used as a 
positive control. Values are expressed as RLU per mg total protein and the 



















Fig 3.2.8 – Estimation of transfection efficiency of different vectors in different 
glioma cell lines as observed by GFP expression. 
The complexes were prepared with PEI25kDa (PEI25), Tat-10H and        


















Fig 3.2.8 – continued. 
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3.2.7 Cytotoxicity of bis(cysteinyl) histidine-rich peptide 
The cytotoxicity caused by the C-5H-Tat-5H-C peptide was evaluated 
in U251 cells. U251 cells were exposed to various N/P ratios of the 
materials for 24 hours. The cell viability assay indicated that the peptide 
displays no cytotoxicity in these cells at N/P ratio up to 20. This was 
remarkably different from the test with PEI25kDa, which caused obvious 
cell death at N/P ratio of 5 and more than 50% cell death at N/P ratio of 20 
(Fig 3.2.9). These results suggested that the C-5H-Tat-5H-C peptide 
maintains the desirable property of low cytotoxicity of peptide-based 












Fig 3.2.9 – Cytotoxicity of bis(cysteinyl) histidine-rich peptide in U251 cells.  
The cells were treated with various N/P ratios of materials for 24 hr. Cell 
viability was determined and expressed as percentage of positive control, 
i.e. the untreated cultures (mean ± SD, n=6). * p<0.001 
 
 
Positive PEI25 C-5H-Tat-5H-C 
U251 * * * 
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3.3 Studies Using Bacterially Produced Polypeptide 
3.3.1 Induced expression and purification of polypeptide 
Successful cloning of BDNF loops 1 and 2 into a cloning vector was 
confirmed by DNA sequencing. The recombinant plasmid was then used to 
transform competent bacteria. Transformants were grown to mid-log phase 
before recombinant protein expression was induced by IPTG for two hours. 
Harvested cells were lysed by lysis buffer and sonication. After removal of the 
insoluble cell lysate by centrifugation, the soluble fraction was purified by 
metal-chelate affinity chromatography. The expression of the recombinant 
polypeptide was confirmed by SDS-PAGE followed by Coomassie blue 






Fig 3.3.1 – Induced expression and purification of recombinant polypeptide. 
Coomassie blue staining (top) and Western blotting against His-tag (bottom) 





Different fractions collected 
after FPLC purification 
14 kD 
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3.3.2 Characterization of DNA/(SPKR)4BL-1,2 Complex 
To access the DNA binding ability of (SPKR)4BL-1,2, DNA retardation assay 
was performed in 1.0% TBE agarose gel. Fig 3.3.2A shows that the mobility of 
plasmid DNA was reduced by (SPKR)4BL-1,2 between N/P ratio of 1.5 and 2, 
indicating complete charge neutralization of DNA. The N/P ratio is defined as 
the number of protonatable nitrogen atoms per DNA phosphate group and is a 
frequently used measure of the charge balance in DNA/polycation complexes. 
In this case, the number of “N” moieties per protein molecule is calculated 
based on the number of basic amino acid residues in the DNA-binding domain, 
which is a total of 8 from the 4 lysine and 4 arginine residues in (SPKR)4. The 
size of the DNA/(SPKR)4BL-1,2 complex was measured by using atomic force 
microscopy. The AFM images (Fig 3.3.2B) revealed that the loosely looped 
structure of plasmid DNA molecules was fully compacted by (SPKR)4BL-1,2 at 























Fig 3.3.2 – Characterization of DNA/(SPKR)4BL-1,2 complex. 
(A) Agarose electrophoresis was carried out for pCAG-luc DNA complexed 
with (SPKR)4BL-1,2 at an N/P ratio from 0 to 3. M: DNA marker lane. 
(B) Atomic force microscopy images of (i) plasmid DNA, (ii) (SPKR)4BL-1,2 
and (iii) DNA/(SPKR)4BL-1,2 complexes (N/P=10) respectively. 




(i) (ii) (iii) 
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3.3.3 In vitro transfection efficiency of DNA/(SPKR)4BL-1,2 
complex in TrkB-receptor-positive cells 
To examine the possibility of using (SPKR)4BL-1,2 as a gene delivery 
vector in TrkB-receptor-positive cells, the transfection efficiency of 
(SPKR)4BL-1,2 was compared to its control (SPKR)4 (a DNA binding 
domain only) in cortical neurons from 15-day foetal rats using a reporter 
gene encoding luciferase protein (pCAG-luc). As shown in Fig 3.3.3A, gene 
delivery by (SPKR)4BL-1,2 was significantly higher than that by (SPKR)4 
with a difference of nearly 1000-fold. (SPKR)4BL-1,2 was also compared 
with commonly used gene carriers PEI25kDa in terms of gene delivery 
efficiency into glial cells from 20-day foetal rats (Fig 3.3.3B). Although 
(SPKR)4BL-1,2 was less efficient in glial cells as compared to PEI25kDa, 
the transfection efficiency was dose-dependent.  
To further investigate the ability of (SPKR)4BL-1,2 in mediating in vitro 
gene delivery, we compared the transfection efficiencies of (SPKR)4BL-1,2 
with or without the addition of PEI600 in cortical neurons from 15-day foetal 
rats using pCAG-luc. To prepare ternary complex composed of DNA, 
PEI600, and (SPKR)4BL-1,2, DNA was first mixed with PEI600 at different 
N/P ratios, complex was incubated for 30 min, and the (SPKR)4BL-1,2 was 
added into the mixture at N/P ratio of 10. Fig 3.3.3C shows that the addition 






Fig 3.3.3 – Luciferase reporter gene transfer by (SPKR)4BL-1,2 in TrkB-
receptor-positive cells.  
Values are expressed as RLU per mg total protein and the SD is indicated 
with error bars (n=4).    
(A) Comparison of gene transfection efficiencies between (SPKR)4 and 
(SPKR)4BL-1,2 in cortical neurons of 15-day foetal rats. 
(B)  Dose-dependent gene expression in glial cells of 20-day foetal rats. 
(C) Comparison of gene transfection efficiencies between (SPKR)4BL-1,2 










3.3.4 Non-specific cellular uptake of (SPKR)4BL-1,2 in TrkB-
receptor-negative cells 
To verify the cell-type specificity of (SPKR)4BL-1,2, several types of 
TrkB-receptor-negative cells were used. Firstly, we transfected PC-12 cells 
using (SPKR)4BL-1,2 and the control (SPKR)4. As shown in Fig 3.3.4A, 
(SPKR)4BL-1,2 was able to give much higher level of gene expression as 
compared to the control (SPKR)4.  
To study the possibility of (SPKR)4BL-1,2 mediated gene delivery via 
p75 neurotrophin receptors, PC-12 cells were pretreated with antibody  
anti-p75 against p75 for 1 hour before transfection to ensure that the p75 
neurotrophin receptors are blocked for the potential binding of other ligands. 
Fig 3.3.4B shows that the transfection efficiency of (SPKR)4BL-1,2 was not 
reduced significantly in pretreated cells as compared to that in untreated 
cells. To study the possibility of (SPKR)4BL-1,2 mediated gene delivery via 
TrkA receptors, transfections by (SPKR)4BL-1,2 were carried out in the 
presence of native NGF and BDNF. The results (Fig 3.3.4C) show that the 
transfection efficiencies were not affected significantly in either case.  
To further evaluate the cell-type specificity of (SPKR)4BL-1,2, 
transfections were carried out in cell-lines without any neurotrophin 
receptors such as NIH-3T3 cells and HeLa cells. As shown in Fig 3.3.5, 
transfection efficiencies of (SPKR)4BL-1,2 were still significantly higher 







Fig 3.3.4 – Luciferase reporter gene transfer by (SPKR)4BL-1,2 in PC-12 cells.  
Values are expressed as RLU per mg total protein and the SD is indicated 
with error bars (n=4).    
(A) Comparison of gene transfection efficiencies between (SPKR)4 and 
(SPKR)4BL-1,2. 
(B) Comparison of gene transfection efficiencies in untreated cells and 
cells pretreated with anti-p75. 
(C) Comparison of gene transfection efficiencies in untreated cells and 
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Fig 3.3.5 – Comparison of gene transfection efficiencies by PEI25kDa, 
(SPKR)4 and (SPKR)4BL-1,2 in NIH-3T3 and HeLa cells.  
Values are expressed as RLU per mg total protein and the SD is indicated 



















































4.1 Studies Using PEI600 Conjugated Synthetic Peptide 
4.1.1 The design of Tat-PEI600 
The most well characterized cell-penetrating peptide is the peptide 
derived from the arginine-rich basic domain of the HIV transactivator of 
transcription (Tat). For gene delivery, several recent publications have 
reported that Tat peptide-mediated in vitro transfection is strongly dependent 
on the presence of chloroquine, a weak base that blocks endosomal 
acidification and induces osmotic swellings of the endosomes leading to 
membrane rupture [79-81]. Since chloroquine co-treatment is not a feasible 
approach for clinical usage, other strategies have to be adopted. Protonable 
amines in polyethylenimines (PEIs), widely used non-viral gene delivery 
vehicles, could be used to replace chloroquine. PEIs are a type of polymer 
with a basic chemical unit of two carbons followed by one nitrogen atom that 
can be linked to form a linear or a branched form polymer. With the high 
density of primary, secondary and tertiary amines, branched PEIs can 
condense negatively charged plasmid DNA to form nanometric particles that 
can be internalized by cells. The amino nitrogen atoms of PEIs can be 
protonated in the acidic endosomal environment, protecting endocytosed 
DNA from lysosomal nuclease degradation. Massive proton accumulation 
can further invoke influx of chloride ion into the endosome, followed by 
osmotic swelling and eventually physical rupture of the cellular organelle, 
thus facilitating the escape of endocytosed DNA to the cytoplasm.  
PEIs with molecular weight (MW) of 25,000 Da or greater have shown 
high transfection efficiency both in vitro and in vivo [38, 40]. Previous 
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publication demonstrated that a Tat-PEG-PEI conjugate (Tat covalently 
coupled to PEI25kDa through a PEG spacer) could be used for lung cancer 
therapy, comprising protection for plasmid DNA and enhanced in vivo 
transfection efficiency [112]. However, the cytotoxicity was not reduced 
significantly at high concentration since PEI25kDa component in the 
conjugate could induce rapid necrotic-like changes resulting from 
perturbation of the plasma membrane and the activation of a mitochondrially 
mediated apoptosis [39].  
On the other hand, low MW PEIs (< 2,000 Da) display much less toxicity 
but almost no transfection activity [113]. Thus in our study, to decrease 
cytotoxicity, a low molecular weight branched polyethylenimine, PEI600 was 
conjugated with Tat peptide. The arginine-rich domain of HIV-1 Tat protein 
(48-60) was taken as a template in the vector design [75]. Since both 
PEI600 and Tat peptide are highly positively charged, they can also help in 
DNA condensation. A glycine residue was inserted between Tat peptide and 
PEI600 to enhance the flexibility of the vector. Hence, the sequence of the 
hybrid vector was GRKKRRQRRRQPPG-PEI600 (Tat-PEI600). 
 
4.1.2 The DNA/Tat-PEI600 conjugate complex  
To prove the concept of using PEI600 for endosomal escape, the 
ternary complexes comprising DNA, PEI600 and Tat peptide were used for 
transfection. PEI600 did improve the transfection efficiency of Tat peptide 
but the considerable variation in gene expression among the samples in 
the group transfected with the ternary complexes was noticeable as well 
(Fig 3.1.1). This inconsistency is probably related to the instability of the 
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complexes. Consistent with this notion, the size and zeta potential of the 
noncovalent ternary complexes increased and decreased, respectively, 
over time (Table 3.1.1).  
In contrast to that observed with noncovalent ternary complexes, 
analysis of biophysical properties of the DNA/Tat-PEI600 conjugate 
complexes demonstrated that the size and zeta potential did not change 
significantly over time, suggesting an improved stability after covalent 
linkage (Table 3.1.2). As anticipated, the improved stability of the DNA/Tat-
PEI600 conjugate complexes contributed to transfection results with higher 
efficiency and less variation, as compared to that of the noncovalent 
ternary complexes (Fig 3.1.3B). The transfection using GFP reporter gene 
also demonstrated that the Tat-PEI600 conjugate can provide similar levels 
of transfection efficiency as that of PEI25kDa, yet without sacrificing the 
biocompatibility (Fig 3.1.3C, Fig 3.1.3D and Fig 3.1.4).  
In brief, a new design for non-viral gene delivery vector is reported, in 
which low MW PEIs are covalently linked to bioactive Tat peptides to form 
a cationic molecular conjugate. This peptide-polymer hybrid has been 
prepared using a versatile methodology to couple synthetic polymers 
directly to resin-supported peptides. The hybrid biomaterial combines the 
unique features of the two original cationic materials and functions as a 
novel gene delivery vector with good biocompatibility.  
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4.2 Studies Using Histidine-rich Synthetic Peptides 
4.2.1 The design of histidine-rich peptides 
Following the success of Tat-PEI600 peptide-polymer hybrid, the 
concept of covalently attach an endosomolytic domain to Tat peptide could 
also be implemented in the design of synthetic peptide-based gene 
delivery vector. To extend this concept, amino acids with side chain having 
pKa values between 5 and 7 are possible candidates to buffer inside early 
endosomes. For instance, the side chain of histidine, which is an imidazole 
ring, has a pKa value of 6.0. The inclusion of histidine residues could have 
endosomal buffering capacity, which can result in a rupture of endosomal 
membrane. Indeed, several studies have shown that histidine-rich peptides 
and polypeptides are capable of mediating gene delivery [95-98]. Hence, it 
was rational to design a synthetic peptide-based vector by replacing 
PEI600 with oligohistidine sequence. The backbone of the design could be 
a highly positively-charged DNA binding domain covalently linked to an 
oligohistidine sequence.  
Based on this assumption, three different histidine-rich peptides were 
designed by using 10H (10 histidines) as endosomolytic domain and 
(SPKR)4, 10K, or Tat as DNA binding domain. (SPKR)4 sequence, derived 
from the C-terminus of histone H1, was previously used as DNA-binding 
domain in recombinant protein [56]. Oligolysine sequence (10K) has also 
been shown to be adequate for DNA binding in peptide design [57, 60]. Tat 
sequence is well known for its cell-penetrating function, but the positively 
charged amino acid rich feature could be useful in DNA binding as well. 
The sequences of the three peptides are shown in the table below. 
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Table 4.2.1 – Sequences of the histidine-rich peptides used in this study. 
 
Name Sequence No of amino acids 
H10K2(SPKR)4 HHHHHHHHHHKKSPKRSPKRSPKRSPKR 28 
10K-10H KKKKKKKKKKHHHHHHHHHH 20 
Tat-10H RKKRRQRRRRHHHHHHHHHH 20 
 
   
4.2.2 Transfection efficiencies of histidine-rich peptides 
The in vitro transfection results in two different glioma cell lines showed 
that Tat-10H is more efficient than the other two peptides H10K2(SPKR)4 
and 10K-10H in N/P ratios of 5 to 20 (Fig 3.2.2). However, the 
characterization of DNA/peptide complexes did not show much difference 
in terms of zeta potential, particle size, or stability (Table 3.2.1). Therefore, 
the biophysical properties of DNA/peptide complexes should not be the 
determining factor of gene delivery. While (SPKR)4 and oligo-lysine 
sequences are only positively-charged sequences without any active 
biological functions, the difference in transfection efficiency could be due to 
the inherent cell-penetrating function or the nuclear importing ability 
provided by Tat sequence.  
Similar to the case of Tat-PEI600, the importance of the covalent 
linkage between Tat and oligohistidine was demonstrated by comparing 
the transfection efficiencies of Tat peptide, mixture of Tat and 10H peptides, 
and Tat-10H peptide. The transfection efficiency of DNA/Tat peptide 
complex was relatively low, probably because of the lack of endosomolytic 
domain (Fig 3.2.3). Co-incubation of the cells with 10H peptides could not 
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improve the transfection efficiency because the cellular uptake of 10H 
peptide will be random in this case, which implies that the chance of having 
DNA/Tat peptide complex and 10H peptide in one endosome is very low. 
However, the DNA/Tat-10H peptide complex ensures that each 
endocytosed complex will have oligohistidine sequence for endosomal 
escape. 
One common method to study the endosomolytic property of histidine-
rich peptide is to carry out transfection in the presence of bafilomycin A1. 
The gene transfer activity of Tat-10H was almost abolished in the presence 
of bafilomycin A1, an inhibitor of vacuolar ATPases known to block the 
acidification of the lumen of endosomes by the endosomal proton pump 
(Fig 3.2.4A). The lack of acidification of endosomes prevents the 
protonation of the imidazole groups of oligohistidine sequence and, as a 
consequence, its endosomolytic activity. Assuming that increasing number 
of histidine residues could increase the transfection efficiency, three 
peptides containing penta- (5), deca- (10), and icosa- (20) histidine 
residues were evaluated. The Tat-5H peptide was not as efficient as Tat-
10H peptide even at high N/P ratio, most probably because the number of 
histidine residues is not sufficient for endosomolytic activity. Unexpectedly, 
Tat-20H peptide was less efficient than Tat-10H peptide although more 
histidine residues should be able to induce endosomolysis more efficiently 
(Fig 3.2.4B). Characterization of DNA/Tat-20H peptide complex showed 
that the polydispersity index value of the complex is higher than 0.4, which 
suggests that the DNA/Tat-20H peptide complex has a very broad size 
distribution as compared to DNA/Tat-10H peptide complex whose 
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polydispersity index value is lower than 0.3 (data not shown). On top of this, 
the particle size of DNA/Tat-20H peptide complex increased over time 
(data not shown). We hypothesized that the steric hindrance imposed by 
imidazole group of histidine residue inhibits effective DNA condensation by 
Tat-20H peptide. Hence the DNA/Tat-20H peptide complex would have a 
propensity to dissociate easily.  
 
4.2.3 The design of bis(cysteinyl) histidine-rich peptides 
The duration of transient gene expression will in part depend on how 
long DNA can survive metabolism [114]. A strategy to improve the stability 
of DNA/peptide complex for use in vivo is to use cross-liking agents such 
as glutaraldehyde [44, 115]. Although cross-linking of DNA/peptide 
complex does increase their metabolic stability, it also diminished their 
ability to mediate gene expression due to the slow reversal of the Schiff 
bases [115].  Another strategy is to use low molecular weight peptide 
possessing cysteine residues that can temporarily form high molecular 
weight peptide following polymerization on DNA [116]. Inspired by previous 
studies using low molecular weight disulfide cross-linking peptides and 
reducible histidine-rich polylysine [99, 116, 117], we designed a 
bis(cysteinyl) histidine-rich peptide, C-5H-Tat-5H-C, based on the Tat-10H 
peptide. Two cysteine residues and ten histidine residues are distributed 
evenly on both ends of Tat sequence. This symmetrical design will facilitate 
easier interpeptide disulfide bond formation between adjacent peptides 
bound to DNA, as compared to another possible design C-Tat-10H-C (Fig 
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4.2.1). A counterpart without cysteine residues, 5H-Tat-5H, was designed 




Fig 4.2.1 – Schematic diagram of interpeptide disulfide bond formation. 
DNA/C-5H-Tat-5H-C peptide complex is formed through ionic binding of the 
peptide to the DNA backbone, followed by interpeptide oxidation to form 
disulfide bonds that reversibly stabilize the complex.  
 
 
4.2.4 The DNA/bis(cysteinyl) histidine-rich peptide complex  
To verify whether the interpeptide disulfide bond will form, the 
DNA/bis(cysteinyl) histidine-rich peptide complexes were incubated for 
different duration of time before transfection into U251 cells. At N/P ratios 
of 3 and 4, the control group which was incubated for only half an hour was 
less efficient than the test group which was incubated for 2 hours under 
vigorous shaking (Fig 3.2.6A). This result suggests that interpeptide 
disulfide bond was formed by air oxidation in the test group. Interpeptide 
disulfide bond formation also appears to decrease the particle size of the 
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DNA/peptide complex, resulting in 30 nm shrinkage (Table 3.2.3). On the 
other hand, it appears that the transfection efficiency of the test group 
inversely correlates with the N/P ratio. A possible explanation is that the 
DNA/peptide complexes prepared at high N/P ratios were too stable to 
dissociate in the cellular reducing environment, because of the increasing 
number of interpeptide disulfide bonds. Similar phenomenon was observed 
in previous studies, which showed that addition of more than two cysteine 
residues in a peptide design exceeds the number of disulfide bonds that 
can be efficiently reduced in the cell [116]. To further demonstrate the 
effect of interpeptide disulfide bond, a counterpart without cysteine 
residues, 5H-Tat-5H, was compared with C-5H-Tat-5H-C peptide using 
transfection in U251 cells. Apparently, the counterpart without cysteine 
residues was less efficient, due to the inability to form interpeptide disulfide 
bond (Fig 3.2.6B). Enhanced luciferase and GFP expression mediated by 
C-5H-Tat-5H-C peptide is observed in most of the glioma cell lines tested, 
as compared to the original design Tat-10H peptide (Fig 3.2.7 and Fig 
3.2.8). Furthermore, the transfection efficiency of C-5H-Tat-5H-C peptide is 
comparable to that afforded by PEI25kDa, yet without showing any sign of 
cytotoxicity (Fig 3.2.9). However, GFP transgene expression is higher in H4 
cells for C-5H-Tat-5H-C peptide than for PEI25kDa. This indicates that the 
percentage of cells transfected with C-5H-Tat-5H-C peptide was higher. 
PEI25kDa tends to delivery multiple copies of plasmid into one cell. Similar 
result was also observed in other publication [118]. 
In conclusion, a bis(cysteinyl) histidine-rich peptide was developed for 
efficient intracellular gene delivery with the potential to be modified for in 
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vivo studies, such as attachment of polyethylene glycol (PEG) to improve 
solubility and inhibit salt-induced aggregation [119]. A stable DNA/peptide 
complex could be easily prepared by forming interpeptide disulfide bonds, 
which can undergo reduction in cellular environment to trigger DNA release. 
The concept of endosomal buffering has also been extended by 
determining the number of histidine residues in a peptide needed to 
enhance gene transfer.  
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4.3 Studies Using Bacterially Produced Polypeptide 
4.3.1 The design of polypeptide 
Based on the findings from histidine-rich peptides, it might be possible 
by combining of oligohistidine, DNA binding domain, and targeting domain 
to create cell-type specific gene delivery vector. A recombinant polypeptide 
approach offers opportunities to produce a polypeptide based-vector by 
incorporating multiple functional domains to overcome the barriers at 
different stages of gene transfer, from cellular internalization, endosomal 
escape, and cytoplasmic transport to nuclear translocation. In our previous 
publication [61], we had successfully designed a recombinant polypeptide 
containing NGF loops 1 and 2 which enable the natural process of 
receptor-mediated endocytosis specifically to target TrkA-receptor-positive 
cells. Using the same concept, a recombinant polypeptide was designed to 
target TrkB-receptor-positive cells. The polypeptide was designed to 
contain: (1) an oligohistidine sequence (10 histidines) for endosomolytic 
property and FPLC purification; (2) a DNA binding domain (SPKR)4; and (3) 
a targeting domain incorporating the BDNF hairpin motif of loops 1 and 2.  
Instead of using the cell penetrating sequence Tat as DNA binding 
domain, (SPKR)4 was chosen to reduce possible non-specific cellular 
uptake. The three-dimensional structure of the targeting domain BDNF 
loops 1 and 2 is stabilized by the disulfide bond formed between an 
artificially introduced cysteine residue and C65 after oxidation. Different 
from a full-length native BDNF, the segment used in the present study 
contains only two residues of cysteine [120]. Thus, mismatched disulfide 
bond linkage, a problem often seen in the production of recombinant 
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polypeptide, is avoided and unfolding/refolding of the recombinant 
polypeptide to form correct disulfide bonds would be unnecessary, making 
this polypeptide preparation relatively easier. The DNA binding and 
targeting domains are linked by an a-helical linker which is flanked by 
flexible glycine residues to allow independent action of both functional 
domains [56]. The polypeptide has 117 amino acid residues and the 
sequence is shown below. 
 
4.3.2 The cell-targeting specificity of polypeptide 
In order to confirm the cell-targeting specificity of the polypeptide, 
cortical neurons and glial cells extracted from foetal rats were used for in 
vitro transfection. Glial cells such as astrocytes and oligodendrocytes are 
known to express fairly large quantities of truncated TrkB receptors on cell 
surface [121]. The transfection in cortical neurons and glial cells suggests 
that BDNF loops 1 and 2 play a part since (SPKR)4 alone was not capable 
to mediate gene delivery (Fig 3.3.3A and Fig 3.3.3B). Furthermore, the 
endosomal escape of DNA/(SPKR)4BL-1,2 complexes is efficient since the 
addition of PEI600, which is known to promote endosomal escape through 
its “proton sponge” property, did not enhance the transfection efficiency 
significantly (Fig 3.3.3C). 
  1-40 MGHHHHHHHH HHSSGHIEGR HMSPKRSPKR SPKRSPKRGG  
 41-80 TYLSEDELKA AEAAFKRHNP TGSCSISEWV TAADKKTAVD  
81-117 MSGGTVTVLE KVPVSKGQLK QYFYETKCNP MGYTKEG 
 
aa     3-12 endosomolytic domain and His-tag for FPLC purification 
aa   23-38 DNA binding domain  
aa 64-117 BDNF loops 1 and 2  
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To further verify the cell-targeting specificity of (SPKR)4BL-1,2, a series 
of transfection experiments was carried out in different cell lines which do 
not express TrkB receptors on cell surface. First, PC-12 cells that express 
TrkA and p75 neurotrophin receptors were tested. The unexpected high 
transfection efficiency of (SPKR)4BL-1,2 in PC-12 cells raised a question 
whether (SPKR)4BL-1,2 mediate gene delivery through p75 neurotrophin 
receptors, which are potential targets of the neurotrophin (NT) family 
members such as NGF and BDNF (Fig 3.3.4A). However, the presence of 
anti-p75 antibodies has no significant effect on transfection efficiencies in 
PC-12 cells (Fig 3.3.4B). Since PC-12 cells also express TrkA receptors 
that are specific for a neurotrophin – nerve growth factor (NGF), the 
sequences of NGF loops 1 and 2 as well as BDNF loops 1 and 2 were 
aligned to check the possibility of cross talk. The sequence alignment 
revealed that the similarity of these two hairpin motifs is more than 40%. 
Also, three-dimensional structures alignment of most of the neurotrophins 
reveal that the regions of similarity are much larger than that suggested from 
sequence alignments [122]. Therefore, it is highly possible that BDNF loops 1 
and 2 could recognize and bind to TrkA receptors. However, the transfection 
efficiencies in PC-12 cells were not reduced significantly in the presence of 
potential competitors such as BDNF and NGF (Fig 3.3.4C). Therefore, 
(SPKR)4BL-1,2 does not mediate gene delivery in PC-12 cells through TrkA 
and p75 neurotrophin receptors. Second, the transfections were carried out 
in cell-lines without any neurotrophin receptors such as NIH-3T3 cells and 
HeLa cells. The results also showed that the presence of BDNF loops 1 
and 2 do not contribute to cell-targeting specificity (Fig 3.3.5). 
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In summary, the results demonstrated that the recombinant polypeptide 
(SPKR)4BL-1,2, which is designed to target TrkB-receptors-positive cells, 
was not specific to any cell type. The non-specificity could be due to the 
failed formation of disulfide bond in BDNF loops 1 and 2, which will lead to 
the loss of cell-specificity. In addition, the overall positive charge of the 
recombinant polypeptide might also contribute to non-specific binding to 
































Our studies were focusing on the development of peptide-based gene 
delivery vectors with cell-type specificity and minimal toxicity. In the first part, 
we tried to improve Tat peptide-mediated transfection that is strongly 
dependent on the chloroquine. Polyethylenimine is chosen to replace 
chloroquine due to its ability to facilitate endosomal escape by destabilizing 
the endosomal membrane within the acidic endosomes. Since the 
DNA/PEI600/Tat peptide ternary complex was unstable for gene transfer, a 
peptide-polymer hybrid vector Tat-PEI600 was synthesized in-house by 
chemically conjugating a low molecular weight polyethylenimine PEI600 to a 
cell-penetrating peptide Tat. Due to the improved stability, the Tat-PEI600 
conjugate was able to provide transgene expression levels similar to that 
afforded by PEI25kDa, yet without sacrificing the biocompatibility. 
To extend the concept of covalently attaching an endosomolytic domain to 
a peptide, pure synthetic peptide-based gene delivery vectors can be 
designed by using oligohistidine that is known to have endosomal buffering 
capacity. Three different histidine-rich peptides were designed by using 10H 
(10 histidines) as endosomolytic domain and (SPKR)4, 10K or Tat as DNA 
binding domain. The in vitro transfection results have shown that Tat-10H was 
more efficient than the other two peptides and oligohistidine can function as 
endosomolytic domain. However, increasing number of histidine residues was 
not able to increase the transfection efficiency and 10 histidines were found to 
be the optimum oligohistidine sequence. To improve the stability of 
DNA/peptide complexes for use in vivo, two cysteine residues were 
incorporated into the peptide design for interpeptide disulfide bond formation. 
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A bis(cysteinyl) histidine-rich peptide, C-5H-Tat-5H-C, was designed based on 
the Tat-10H peptide. This symmetrical design will facilitate easier interpeptide 
disulfide bond formation between adjacent peptide bound to DNA. The 
particle size of DNA/C-5H-Tat-5H-C peptide complex was decreased after 2 
hr incubation with shaking due to formation of interpeptide disulfide bond by 
air oxidation. Enhanced transfection efficiency of C-5H-Tat-5H-C was  
observed in most of the glioma cell lines tested, as compared to the Tat-10H 
peptide and 5H-Tat-5H peptide. Moreover, the cytotoxicity was insignificant. 
To achieve cell-type specificity, a multi-domain recombinant polypeptide 
(SPKR)4BL-1,2 was constructed for gene transfer to cells expressing BDNF 
receptor TrkB. The cell-targeting domain was derived from BDNF loops 1 and 
2. Instead of using Tat as DNA binding domain, (SPKR)4 was chosen to 
reduce non-specific cellular uptake due to cell penetration. Similarly, 
oligohistidine was included for endosomal escape. The recombinant 
polypeptide was able to facilitate gene delivery to TrkB-receptor-positive cells 
in a dose dependent manner. However, it could also non-specifically transfect 
the TrkB-receptor-negative cells. 
In conclusion, a panel of biocompatible peptide-based gene delivery 
vectors were developed to overcome potential problems inherent in viral gene 
delivery vectors. Although the recombinant polypeptide was not able to target 
specific cells, it was a step forward to the realization of using non-viral vectors 
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Amino acid sequences of synthetic peptides 
Peptide name Sequence No of amino acids 
Tat-PEI600 GRKKRRQRRRQPPG-PEI600 –   
H10K2(SPKR)4 HHHHHHHHHH-KK-SPKRSPKRSPKRSPKR 28 
10K-10H KKKKKKKKKK-HHHHHHHHHH 20 
Tat-10H RKKRRQRRRR-HHHHHHHHHH 20 
C-5H-Tat-5H-C C-HHHHH-RKKRRQRRRR-HHHHH-C 22 
5H-Tat-5H HHHHH-RKKRRQRRRR-HHHHH 20 
 
 
Amino acid sequence of recombinant polypeptide (SPKR)4BL-1,2 
  1-40 MGHHHHHHHH HHSSGHIEGR HMSPKRSPKR SPKRSPKRGG  
 41-80 TYLSEDELKA AEAAFKRHNP TGSCSISEWV TAADKKTAVD 
81-117 MSGGTVTVLE KVPVSKGQLK QYFYETKCNP MGYTKEG 
 
Features: 
Molecular weight ≈ 14,000 Dalton 
aa   3-12 endosomolytic domain and His-tag for FPLC purification 
aa 23-38 DNA binding domain  
aa 64-117 BDNF loops 1 and 2  
 
